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ABSTRACT OF DISSERTATION 
 
THE ROLE OF OXIDATIVE STRESS AND T CELLS IN THE DEVELOPMENT OF 
MURINE SYNGENEIC GRAFT-VERSUS-HOST-DISEASE 
 
Syngeneic graft-versus-host disease (SGVHD) is induced by reconstituting 
lethally irradiated mice with syngeneic BM cells followed by a 21 day treatment with the 
immunosuppressive agent cyclosporine A (CsA). Clinical symptoms of the disease 
appear 2-3 weeks following cessation of CsA therapy and disease-associated 
inflammation occurs primarily in the colon and liver.  
The development of SGVHD is a complex process resulting from the cooperative 
interaction of multiple effector cell populations including NK cells, T cells and 
macrophages. TH1 cytokines (IL-12, TNF-α, IFN- γ), produced by these effector cells, 
serve as inflammatory mediators contributing to the pathogenesis of SGVHD. The 
SGVHD conditioning agents, irradiation and CsA, are both required for the development 
of disease and contribute to the production of oxidative stress. Time course studies 
revealed increased reactive oxygen and nitrogen species (ROS/RNS), as well as, 
increased colon mRNA levels for TNF-α and iNOS in CsA-treated versus control BMT 
animals. Since ROS/RNS are known to mediate CsA toxicity, studies were undertaken to 
determine the effect of oxidative stress on the induction of SGVHD. In vivo treatment 
with the antioxidant MnTBAP caused a reduction in colon mRNA levels for iNOS and 
TNF-α, as well as delayed disease development, suggesting a role for oxidative stress in 
the development of SGVHD. 
 In addition, CD4+ T cells have been shown to play an important role in the 
inflammatory response observed in the gut of SGVHD mice. Time course studies 
revealed significant increases in the migration of CD4+ T cells as early as day 14 post-
BMT into the colon of CsA mice as well as significant elevated mRNA levels of cell 
adhesion molecules. Homing studies revealed that a labeled CD4+ T cell line, generated 
from SGVHD mice, migrated in larger numbers into the gut of CsA-treated mice 
compared to control animals. This study demonstrated that CD4+ T cells responsible for 
the pathogenesis observed in murine SGVHD are present early after BMT in colons of 
CsA-treated mice, suggesting that during the 21 days of immunosuppression therapy 
functional mechanisms are in place that result in increased homing of effector cells to 
colons of CsA-treated mice. 
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tetrakis (4-benzoic acid) porphyrin (MnTBAP), Cell Adhesion Molecules (CAM), β7 
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CHAPTER ONE: INTRODUCTION 
1.1 Bone Marrow Transplantation 
Bone marrow transplantation (BMT) is a medical procedure that was first applied 
in 1968 to treat severe combined immunodeficiency diseases (SCID). In these studies 
bone marrow (BM), taken from a major histocompatibility complex (MHC)-matched 
donor, was able to correct the immunological deficiency of a patient with Wiscott-
Aldrich Syndrome (WAS) [1]. Since its first successful use, BMT/hematopoietic stem 
cell transplantation (HCT) has been used as a treatment of choice for many diseases (i.e. 
leukemia, aplastic anemia, immune deficiency disorders, etc.). The major complications 
of BMT, graft rejection and graft-versus-host disease (GVHD) are the direct consequence 
of human leukocyte antigen (HLA) (in mouse major histocompatibility complex, (MHC)) 
polymorphisms. The major HLA are essential components of the immune system and 
have different functions. HLA class I antigens (A, B and C) present to T cells peptides 
that are derived from endogenous cell components (or of viral origin), which are 
produced from digested proteins that are broken down in the proteosomes. CD8+ killer T 
cells are activated by the foreign antigens presented by HLA class I antigens and are the 
effector cells responsible for the destruction of intracellular pathogens. HLA class II 
antigens (DP, DQ and DR) present exogenous antigens derived from outside of the cell to 
CD4+ T helper cells [2].  Helper T cells can be classified as to the types of cytokines they 
produce and the nature of the adaptive immune response they generate.  CD4+ T helper 1 
(TH1) cells enhance cellular immune responses against intracellular pathogens via the 
production of interferon γ (IFN-γ), that enhances macrophage activation and killing [2, 
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3].  TH2 cells are involved in enhancing humoral immune responses via the production of 
interleukin 4 (IL-4) and IL-5 [2, 3].  Finally, a recently described population of T helper 
cells, TH17 cells, secrete IL-17 and participate in the response against extracellular 
pathogens [4, 5].   
The immune system uses the histocompatibility antigens to differentiate self from 
non-self.  Upon infection, antigen presenting cells (APC) recognize the pathogen by their 
surface receptors (i.e toll like receptors (TLR)/pattern recognition receptors) and allow 
binding by common constituents in the cell surface of the pathogen (i.e lipids, 
carbohydrates, peptides or nucleic acids). This interaction allows the APC to engulf the 
foreign pathogen through a process called phagocytosis. The ingested pathogen is 
contained within a vesicle called phagosome that fuses with lysosomes, which are 
acidified organelles containing degradative enzymes, to form a phagolysosome. 
Lysosomal enzymes degrade the pathogen into small pieces. After encountering the 
pathogen and taking it up in infected tissue, the APC becomes activated/mature and 
carries pathogen antigens to peripheral lymphoid organs where they present them to T 
lymphocytes [2]. This process allows for the digestion of proteins into small peptides, 
which are then presented by self MHC class II to T helper cells or MHC class I to CD8+ 
T cells. This allows for immune responses to take place and elimination of the pathogen. 
As the response is generated in the context of self-MHC, known as MHC restriction, self-
reactivity is avoided.  As T cells mature in the thymus, they first recognize peptides 
bound to self MHC expressed by thymic APC. Immature T cells, capable of binding to 
self-peptide-self MHC complexes at a proper affinity, undergo positive selection. If these 
immature T cells have high affinity and/or cross reactivity for these self-peptides/MHC 
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complexes they are eliminated by negative selection to avoid autoimmunity. Mature T 
cells exit the thymus and migrate to the periphery where they encounter APC with 
foreign-peptide-self MHC antigens and initiate an immune response. If on the other hand, 
they encounter APC expressing self-peptides they do not react, a concept known as self 
tolerance which prevents autoimmunity. However, if these T cells react to MHC 
molecules, that they did not encounter during thymic development, it can lead to 
alloreactivity. More than 1% of T cells can be activated by foreign (allogeneic) MHC 
molecules [2].  This is a very high percentage relative to that observed in an immune 
response to nominal antigen where the frequency of reactive T cells is on the order of 
1:50,000–300,000 T cells in unprimed individuals and ~1:1000–10,000 T cells in primed 
individuals [6, 7].  
The two major complications of allogeneic BMT are graft rejection and GVHD 
which develop when T cells from one individual recognizes the other’s individuals MHC 
as foreign and respond against it [2, 8]. MHC polymorphisms are not the only donor-host 
disparities that are involved in graft rejection. Differences in minor histocompatibility 
antigens (miHA) can also cause the graft to be rejected slowly as well as to induce 
GVHD [2, 9, 10]. Minor histocompatibility antigens are peptides derived from allogeneic 
proteins that exist in various isoforms and can affect the fate of a graft by provoking cell-
mediated immune responses [9, 11].  In mice and other species there are at least 30 such 
antigens [12]. While CD4+ and CD8+ participate in the immune response directed against 
MHC antigens, CD8+ T cells are mainly responsible for immunity directed against miHA 
[13, 14].   
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Bone marrow transplants are classified based on the source of the donor marrow: 
syngeneic if the BM is from an identical twin, autologous if it is isolated from the patient 
or allogeneic if it is isolated from a HLA-matched sibling or unrelated donor. Allogeneic 
BM recipients usually receive pretransplant conditioning regimens which include high 
doses of chemotherapy and/or irradiation [15-18]. This therapy allows for the maximal 
destruction of the abnormal cells causing the disease, typically malignant cells, as well as, 
to eliminate the recipient’s hematopoietic/immune system that is required to avoid 
immune responses against the donor cells and to allow proper engraftment, i.e. prevent 
graft rejection [19, 20]. Alloantigens associated with the MHC molecules (Human: HLA-
A, B, C, DR, DQ; Mouse: H-2, I-E, I-A and miHA) are the major target of alloreactive T 
cells that mediate patient immune reactivity against the donor BM underlying graft 
rejection and GVHD after BMT [20, 21]. Most transplants preferentially take place 
between donor and recipients that are HLA-matched siblings over HLA-matched 
unrelated donors to reduce the possibility of graft rejection. During graft rejection, the 
host's immune system initiates an effective response in which T lymphocytes recognize 
the allo-MHC antigens as foreign and attack the transplanted tissue and destroy it [2]. 
Because of this destructive immune response, tissues from the patient and from potential 
donors must be typed and matched as completely as possible before transplants are 
performed to reduce the probability of graft rejection. Santos et al. described three 
prerequisites for an effective conditioning to take place. First, the regimen must suppress 
the recipient’s immunity to avoid graft rejection. Second, it must create a “space” in the 
marrow microenvironment to allow establishment and growth of hematopoietic 
progenitors. And third, for patients with malignant diseases, the conditioning must have 
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an antitumor effect to eradicate residual tumor cells [22]. Thus, unless the recipient and 
donor are identical twins, all recipients receiving BMT should undergo 
immunosuppressive therapy.  
1.2 Allogeneic graft-versus-host disease 
Graft-versus-host disease remains a major complication following allogeneic 
BMT. In 1967, Billingham described three requirements for GVHD to take place: First, 
the graft must contain immunologically competent cells (which are now known to be T 
cells); second, the recipient must express tissue antigens that are not present in the 
transplant donor; and third, the patient must be incapable of mounting an effective 
response to eliminate the transplanted cells [23]. GVHD takes place when T cells in the 
graft respond to HLA proteins on host cells and the frequency of this disease is directly 
related to the degree of mismatch that exists between HLA proteins [24]. Reports show 
that GVHD occurs in 25-60% of patients who receive BM from an HLA-identical related 
donor and in 45-70% of recipients from matched unrelated donor [15, 25, 26]. As a 
consequence, approximately 50% of patients who might benefit from BMT cannot find a 
suitable match related or unrelated donor to be able to benefit from this therapeutic 
option.  Ferrara et al. has described the pathophysiology of GVHD as a multifaceted 
process that occurs in  three stages [17, 27]: (1) preconditioning regimens (i.e. high doses 
of chemotherapy) results in damage to host tissues leading to increased proinflammatory 
rmed inces, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), 
amplified expression of adhesion molecules and MHC antigens in target organs 
(intestine, liver skin) [28-31] allowing the migration of effectors cells to the site of 
inflammation; (2) recognition of alloantigens on host APC by donor T cells, results in T 
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cell proliferation, differentiation and secretion of TH1 cytokines (IFN-γ and IL-2); and (3) 
effector cell activation (i.e. macrophages, natural killer cells, cytotoxic T lymphocytes) 
that act in concert with the cytokines described above to cause further tissue injury. 
Finally, it has been demonstrated that mature alloreactive T cells that contaminate the 
marrow and which are responsible for the second stage of this disease are able to initiate 
two forms of GVHD: acute and chronic [17].  
In clinical GVHD, the acute phase is observed during  the first 100 days post-
transplant and is considered the major challenge of patients because of its high 
association with morbidity and mortality [32]. This stage is associated with damage to the 
liver (cholestatic hyperbilirubinaemia), skin and mucosa (maculopapular skin rash) and 
gastrointestinal (GI) tract (nausea, anorexia, watery and/or bloody diarrhea and severe 
abdominal pain) [26, 27]. The chronic phase normally occurs after 100 days and it 
adversely influences long-term survival. In addition to the organs damaged by acute 
GVHD, the chronic phase also affects nails, mouth, eyes, muscles, connective tissues, 
lung, kidneys, heart, marrow and female genitalia [27, 33]. Severity of acute GVHD is 
scored by the extent of involvement of the three main target organs (skin, liver and GI): 
grades are I (mild), II (moderate), III (severe), and IV (very severe). Severe GVHD has 
poor prognosis, with 25% long-term survival (5 years) for grade III disease and 5% for 
grade IV [34]. The relationship between acute and chronic GVHD is controversial. While 
some findings support the idea that the chronic phase is an extension of the acute stage 
[35, 36], others suggest that they appear separately [37, 38]. Atkinson et al. reported that 
acute and chronic are different diseases but share similar risk factors (HLA disparity, 
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female → male transplant, recipient age, etc.) and that the major risk factor for chronic 
GVHD is the prior occurrence of acute GVHD [36].  
Mouse models have been important in the classification and understanding of the 
processes underlying GVHD. Different effector cells have been associated with the 
development of GVHD depending on the type of mismatch involved in the transplant. 
When donor and recipient differ at MHC Class II, CD4+ T cells have been reported to be 
the effector cells responsible for the disease process [21, 39]. Conversely, when donor 
and recipient differ at MHC Class I, CD8+ T cells are associated with disease induction 
[21, 40]. Meanwhile, the effector cells that cause GVHD in miHA mismatch models 
depends on the combination of strains used [41]. When the type of TH immunity that was 
involved in the development of GVHD was analyzed, acute GVHD was dominated by a 
TH1 response while the T cell response during chronic GVHD is driven primarily by a 
TH2 type, characterized by the production of IL-4 and IL-10 cytokines [42, 43] and the 
production of autoantibodies [44].  Although the work is ongoing, recent studies within 
the last year or so have demonstrated a role for TH17 immunity in the development of 
GVHD [45, 46]. 
Many approaches have been used over the years to minimize GVHD following BMT. 
One strategy includes T cell depletion (TCD) from the donor inoculum which has been 
reported to decrease GVHD but this treatment has been associated with increased rates of 
graft failure and relapse [25, 47, 48].  Reisner et al. demonstrated that depletion of T 
cells, with soybean or peanut agglutination, from mouse bone marrow and spleen cells 
suspensions resulted in successful reconstitution of lethally irradiated mice without 
complications due to GVHD [47]. In 1981, Valera et al. reported that ex vivo depletion of 
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T cells, with the use of monoclonal antibody against Thy 1.2, in a murine transplant 
model receiving MHC-mismatched BM prevented GVHD, indicating a role for T cells in 
this disease [48]. Due to the success of studies in animal models, human clinical trials 
using various methods of TCD have been used [25, 49]. These trials confirmed the low 
incidence of GVHD observed in animal models but was also accompanied by other 
limitations (i.e. graft rejection, delayed immune reconstitution, increased rate of disease 
relapse) that did not improve overall survival. Another approach that has been used to 
control GVHD after BMT includes the use of immunosuppressive drugs such as 
cyclosporine A (CsA), prednisone, and methotrexate. These agents by themselves 
typically fail to completely diminish GVHD but therapies using drug combination has led 
to better prognosis [50, 51]. One problem is their lack of specificity since they affect 
many immune responses indiscriminately, causing the patients to be more susceptible to 
opportunistic infections as well as causing toxicity to several organs [52].  
Graft-versus-host disease remains the major limitation of allogeneic BMT since it 
causes significant morbidity and mortality in patients undergoing such treatment [32]. 
The efficacy of allogeneic BMT has been accredited to an allogeneic graft-versus-tumor 
(GVT) response that is associated with the development of GVHD [53]. However, 
because of the toxicities and risks associated with this procedure only a few patients can 
benefit from allogeneic BMT. Meanwhile, autologous BMT is less toxic and does not 
lead to GVHD development since the use of autologous stem cells eliminates donor anti-
recipient alloreactivity. Nonetheless, an increase in relapse is associated with this method, 
presumably due to the lack of an allogeneic GVT response [32], suggesting that T cells 
present in the donor marrow graft are necessary to mediate this response. Thus, the 
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manipulation of the system during the post-transplantation period following autologous 
BMT in order to induce a GVT response, could be beneficial to patients without the 
allogeneic BMT limitations. 
1.3 Syngeneic graft-versus-host disease (SGVHD) 
Syngeneic GVHD was described by Glazier et al. as a GVHD-like syndrome that 
developed in rats following syngeneic BMT and cyclosporine A (CsA) treatment [16]. In 
the rat SGVHD model pathology was observed in the intestine, liver, skin and tongue that 
was similar to that observed in allogeneic GVHD. Due to these similarities in pathology 
and the use of BMT, this disease was termed CsA-induced syngeneic GVHD. Further 
studies revealed that upon cessation of CsA therapy, an acute phase occurred during rat 
SGVHD that was characterized by the infiltration of lymphocytes, mainly CD8+ T cells 
and destruction to the epithelium in target organs. This response was followed by a 
chronic phase that consisted of further damage to the epidermis (fibrosis and 
scleroderma) and dominated by CD4+ T cells [54].  
Syngeneic GVHD can be induced in mice by reconstituting lethally irradiated 
animals with syngeneic BM cells followed by a 21 day treatment with 
immunosuppressive agent cyclosporine A (CsA) [55]. Clinical symptoms of the disease, 
which include weight loss and diarrhea, appear 2 to 3 weeks after cessation of CsA 
therapy.  Similar to acute GVHD in murine models, SGVHD-associated inflammation 
occurs primarily in the colon and liver [55].  Three conditions are required for the 
induction and development of SGVHD: First, the recipient must have a thymus. Second, 
the thymus must be in the field of irradiation. Previous work has shown that 
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thymectomized animals do not develop SGVHD [56]. Third, animals have to be 
irradiated for optimal induction of the disease. Disease does not develop in normal 
animals treated with CsA alone [57] or following adoptive transfer of T cells from 
diseased animals into secondary recipients that are not irradiated [57, 58]. Finally, CsA 
therapy is required for disease induction since animals undergoing syngeneic BMT that 
do not receive CsA treatment have been shown not to develop SGVHD [16].  
As mentioned above, CsA is an immunosuppressive drug that has been used 
clinically [59] and experimentally [18] to prevent graft rejection following solid organ 
transplantation and to prevent GVHD following allogeneic BMT. This 
immunosuppressive drug is derived from Tolypocladium inflatum, a soil fungus. It blocks 
T-cell proliferation by inhibiting the phosphate activity of calcineurin, a Ca2+-activated 
enzyme. Calcineurin is an important phosphatase involved in signaling transmission from 
the T cell receptor (TCR) to the nucleus. Upon its activation, calcineurin 
dephosphorylates nuclear factor of activated T cells (NFAT), rendering it active and 
capable of migrating into the nucleus to induce the transcription of NFAT-dependent 
genes. CsA inhibition of the calcineurin signaling pathway in T cells ultimately inhibits 
the clonal expansion of activated T cells [2, 60](see Figure 1.1). CsA has various 
biological effects on T cells, including the downregulation of proinflammatory cytokines 
[61, 62]. Studies have shown that CsA can impair T cell function by blocking the 
production of IL-2 in activated T lymphocytes, observed by decreased levels of IL-2 
mRNA [63, 64]. In addition, in vitro studies have shown that CsA can reduce the 
production of IL-15 and TNF-α through the upregulation of IL-10 in cell culture of 
rheumatoid synovial fibroblasts [62]. And inhibition of IL-15-induced IL-17 production 
11 
 
in CD4+ T cells have been reported after CsA treatment [61]. Long-term treatment with 
CsA results in toxicities in the kidney and liver.  CsA therapy has been shown to cause 
tubular injury, with interstitial cell proliferation, extracellular matrix deposition and the 
infiltration of macrophages into the interstitium of the kidney [65].  CsA treatment has 
also been reported to affect liver pathology by causing hepatocyte damage, necrosis [66, 
67] and cholestasis [68]. CsA induced hepatotoxicity includes impairment of antioxidant 
enzymes [66, 67] as well as disorganization of the canalicular bile salt export pump 
transporter mechanism [69]. Finally, CsA treatment has been shown to affect the thymus 
and consequently T cell maturation [70]. There is evidence that CsA therapy in animals 
leads to damages of the thymic architecture and the medullary region [71] that may affect 
negative selection of immature thymocytes and has been proposed to mediate the 
development of SGVHD following lethal irradiation, syngeneic BMT and treatment with 
CsA [70].  
1.4 Role of T cells in SGVHD 
The role of T cells as an effector cell population has been well established in the 
rat model of SGVHD. Various studies have demonstrated the role of CD4+ as well as 
CD8+ T cells in the induction and development of rat SGVHD [56, 72]. The disease in 
the rat model is characterized by an early acute phase mediated by CD4-CD8+ T cells, 
that takes place within the first week after the cessation of CsA treatment, followed by a 
chronic phase that is dominated by double positive T cells (CD4+CD8+) [54]. Finally, rat 
SGVHD can be adoptively transferred into secondary irradiated animals by T cells 
isolated from diseased animals [57, 72].   
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The major effector cells in rat SGVHD were originally described as cytotoxic 
CD8+ T lymphocytes that were specific for MHC class II antigens [73]. It is interesting 
that the CD8+ autoreactive T cells promiscuously recognize MHC class II molecules [74].  
This observed association is aberrant in that CD8+ T cells typically recognize antigen in 
the context of MHC class I molecules.  It was later shown that these effector cells were 
specific for the class II-associated invariant chain peptide CLIP [73].  This peptide is 
generated during the trafficking of MHC class II to the surface of the cell. The invariant 
chain binds to the newly synthesized MHC class II molecules and blocks the binding of 
peptides and unfolded proteins in the endoplasmic reticulum and during the transport of 
the MHC class II molecule into acidified endocytic vesicles. In these vesicles, proteases 
cleave the invariant chain, leaving the CLIP peptide attached to the binding groove of the 
MHC class II molecule. Endocytic antigens (pathogens and their proteins) are degraded 
to peptides in the endosome but cannot bind to MHC class II molecules that are occupied 
by the CLIP peptide. Once CLIP is bound to the MHC class II molecule, it cannot bind 
other peptides thus inhibiting their upload and delivery to cell surface were they can be 
presented to effector cells [2, 75]. For CLIP to be removed from the binding groove of 
the MHC class II molecule it requires the action of the MHC like-molecule, DM (HLA-
DM for human and H-2M for mouse), which is encoded in the MHC locus and resides in 
the endosome. DM catalyses the dissociation of CLIP and stabilizes the MHC class II 
molecule so it can interact with antigenic peptides in the endosome. Once a stable 
peptide/MHC class II complex forms, DM disassociates and the complex transits to the 
cell surface of MHC class II expressing cells [75]. Further characterization revealed that 
the reactivity of CD8+ autoreactive T cells from SGVHD rats with MHC class II 
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molecules bearing CLIP was based on the specific interaction of the N-terminal flanking 
region of CLIP/MHC class II and the Vβ segment of the TCR to initiate a pathogenic 
immune response. Fischer et al. demonstrated that the CD8+ autoreactive T cell 
population in rat SGVHD predominantly expresses Vβ 8.3/8.5 TCR and adoptive transfer 
of these cells (Vβ 8.5+CD8+ T cells) could promote SGVHD in secondary recipients [76].  
However, clonal analysis of these regions revealed that not only the N-terminal flanking 
region on CLIP could stimulate T cells but that the C-terminal region presented in the 
context of class II could also activate SGVHD T cells. However, only the cells that were 
specific for the N-terminal region of CLIP were pathogenic in vivo, while clones 
requiring the C-terminal region were nonpathogenic [74].  It is interesting to note that the 
pathogenic CLIP-reactive T cell clones have the ability to produce TH1 cytokines (IL-2 
and IFN-γ), that mediate the acute phase of the disease, while the nonpathogenic C-
terminal-reactive clones produced TH2 cytokines (IL-4 and IL-10), that are associated 
with the chronic disease stage [77]. These studies demonstrated that an autoreactive, 
pathogenic CD8+ T cell response was associated with the generation of rat SGVHD. 
However, while the induction protocol and tissue pathology were similar between the rat 
and mouse models of SGVHD, data will be presented demonstrating that the effector 
mechanisms underlying the murine model of SGVHD appear to be very different from 
that observed in the the rat model of this inducible disease.  
Immunohistochemical (IHC) analysis has demonstrated an increased presence of 
CD4+ and CD8+ T cells in the colonic lesions of mice with SGVHD [78]. However, 
murine SGVHD appear not to be mediated by CD8+ T cells, since cytotoxic T cell 
responses were not demonstrated in this disease model [79]. Recently, the role of CD4+ T 
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cells in the development of murine SGVHD was clearly established [58, 78]. First, as 
described above, IHC analysis revealed an increased presence of CD4+ T cells in the 
SGVHD colon.  Upon isolation and characterization of immune cells from the colons of 
SGVHD mice, it was shown that increased numbers of CD4+ T cells were present in the 
colons of diseased animals compared to BMT control and normal mice [78]. The 
percentage and numbers of CD8+ T cells did not change between the diseased and control 
animals. To determine if the increase in CD4+ T cells in the colons of SGVHD mice was 
functional, in vivo T cell depletion studies were employed.  The use of a monoclonal 
antibody (mAb) cocktail against T cells during the post-CsA period failed to inhibit 
disease [80] and subsequent analysis revealed that antibody treatment was able to remove 
peripheral CD4+ T cells but not colonic T cells [78]. Thus, Ab therapy after cessation of 
CsA therapy failed to eliminate T cells from the colons of treated animals and did not 
alter disease induction.  Expanding on these studies, specific mAb against CD4+ or CD8+ 
T cells were utilized following myeloablative conditioning and during the 21 days of CsA 
therapy period to inhibit T cell migration into the gut and to determine the role of these T 
cell subsets in the development of SGVHD.  Treatment during this period specifically 
removed CD4+ or CD8+ by day 21 post-BMT.  Depletion of CD4+ T cells, but not CD8+ 
cells, significantly reduced the induction of clinical symptoms as well as pathology 
associated with murine SGVHD [78]. These findings were supported by additional 
experiments demonstrating that CD4+ T cells isolated from SGVHD mice were capable 
of inducing disease when adoptively transferred into irradiated secondary recipients [58]. 
Taken together, these studies demonstrated that the presence of CD4+ T cells in the 
colons of CsA-treated mice during the induction period is critical for disease 
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development. In addition,  Bryson et al. [58] have shown that CD4+ T cells isolated from 
the spleen and mesenteric lymph nodes from SGVHD had increased proliferative 
responses against dendritic cells (DC) pulsed with a bacterial lysate prepared from the 
cecum of normal mice. CD4+ T cells from SGVHD mice did not respond against 
syngeneic/self APC (unpulsed DC or splenic APC), or DC pulsed with self epithelial 
antigens, nominal protein antigens or food-derived antigens, demonstrating a specificity 
for bacterial antigens. With the similarity between SGVHD-intestinal inflammation and 
murine models of colitis and the dependency of colitis models on bacterial specific T 
cells [81, 82], we hypothesized that bacterial-specific CD4+ T cells may mediate the 
induction of murine SGVHD.  Thus, based on the phenotype of the major effector cells, 
as well as, putative antigen specificity, it is clear that while SGVHD is induced via 
similar protocols, the T cell response is demonstrably different in the rat and mouse. 
1.5 Proinflammatory mediators and SGVHD 
Previous studies demonstrated significantly higher levels of mRNA for the TH1 
cytokines IL-12, interferon-γ (IFN-γ) and TNF-α in target organs of mice that had 
developed SGVHD.  In vivo depletion of IL-12 [80], as well as TNF-α [83], inhibited the 
development of the disease suggesting a role for TH1 cytokines in the development of 
murine SGVHD [80]. The role of macrophages in this inducible disease was documented 
by Flanagan et al. [83]. Activated macrophages were present in SGVHD mice.  These 
animals were more responsive to sublethal doses of LPS relative to control animals.  As 
macrophages are a major source of IL-12 and TNF-α and are responsive to LPS and other 
bacterial products through interaction with toll-like receptors [84] it was concluded that 
activated macrophages play a major role in the development of SGVHD. Thus, activation 
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of macrophages could lead to an increased release of proinflammatory cytokines, 
resulting in enhanced production of IL-12 and TNF-α, cytokines which were shown to 
contribute to the development of murine SGVHD [80, 83].    
 1.6 Oxidative Stress and SGVHD 
Both radiation and CsA are required for the development of SGVHD [57, 85] and 
participate in the induction of oxidative stress [65, 86-88]. Radiation allows for the 
elimination of regulatory cells that are present in normal mice and are capable of 
modulating the induction as well as the adoptive transfer of SGVHD [58, 73]. Irradiation 
is also required to prolong the alterations in thymic architecture induced by CsA 
treatment which has been proposed in the rat model to alter thymocyte maturation 
resulting in the generation of self-reactive T cells [71]. Finally, it has been demonstrated 
that cell killing by ionizing radiation is mediated primarily through the induction of 
oxidative stress [89-91]. Several toxicities are also associated with the use of CsA 
immunosuppression. CsA-associated side effects include damage to the vascular 
endothelium via the production of reactive oxygen species (ROS) [86-88, 92]. 
Administration of CsA to rats has been shown to cause overproduction of ROS, measured 
by increased levels of 2’,7’-dichlorofluroscein (DCF) and malondialdehyde (MDA) as 
well as increased RNS shown by elevated iNOS and nitrotyrosine levels [87, 88]. Also, 
CsA-induced oxidative stress has been shown to activate some transcriptional factors, 
such as nuclear factor kappa B (NF-kB), leading to the activation of gene transcription of 
proinflammatroy molecules, including ROS/RNS mediators [93].  
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In addition to the generation of ROS by conditioning agents, oxidative signals can 
also be induced by cytokines. Tumor necrosis factor-α, is a prime example and is 
regulated transcriptionally by NF-κB, which is a ubiquitous transcription factor 
implicated in the induction of many cytokines and adhesion molecules involved in 
immune and inflammatory responses [27, 94]. The NF-κB family of transcription factors 
is composed of five members: p65 (REL-A), REL-B, cytoplasmic c-REL, p50 and p52 
which function as homo- or heterodimers. NF-κB dimers are sequestered in the 
cytoplasm in an inactive form which is bound to the inhibitor molecule IκB. Tumor 
necrosis factor-α signaling mediates the phosphorylation of IκB via a kinase complex 
leading to the polyubiquitination and proteosome-mediated degradation of the inhibitor 
and allowing for the release of the NF-κB factors. Free NF-κB dimers can then 
translocate to the nucleus and activate gene transcription of proinflammatory molecules 
[95, 96]. 
The development of SGVHD is a multi step process resulting from the 
cooperative interaction of various effector cell populations, including NK cells [80], T 
cells [78, 97] and macrophages [83], along with TH1 cytokines that result as a 
consequence of the preconditioning regimes during the induction the disease [80, 83]. 
However, the mechanism of action of these proinflammatory cytokines in SGVHD 
remains unclear.  A possible mechanism could be via their stimulation of oxidative stress, 
including the production of nitric oxide (NO) [98]. Nitric oxide is a ubiquitous molecule 
needed for normal physiologic functions but it is also associated with several pathologic 
diseases including GHVD [98-102]. Nitric oxide is generated from L-arginine through an 
oxidation reaction that is catalyzed by NO synthase (NOS)(see Figure 1.2). It can be 
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produced via constitutive and inducible forms of the NO synthase (iNOS, NOS2) 
enzyme. The constitutively expressed forms are found in vascular endothelial cells 
(eNOS, NOS-3) or in neuronal cells (nNOS, NOS-1). The inducible form of NOS (iNOS) 
can be expressed in many cell types including macrophages, neutrophils, endothelial cells 
and hepatocytes; it also has immunosuppressive properties that may play a role in the 
downregulation of immune responses [98]. It is known that activated macrophages have 
the ability to produce large amounts of nitric oxide (NO), via the iNOS (NOS2) enzyme 
[103] . Since studies revealed a role for macrophages in SGVHD, due to IL-12 secretion, 
and they are known to produce NO, the contribution of this inflammatory mediator to the 
development of murine SGVHD was studied during the active disease period (after 
cessation of CsA therapy). The functional role for NO was determined by the treatment 
of mice with the iNOS inhibitor aminoguanidine (AG) [104]. Inhibition of iNOS resulted 
in the abrogation of clinical symptoms, tissue pathology and cytokine (IL-12 and IFN-γ) 
levels associated with the development SGVHD [100]. Nitric oxide has also been studied 
in animal models of allogeneic GVHD.  Inhibition of iNOS also resulted in reduced 
development of pathophysiology (i.e. tissue injury, intestinal pathology, reduced 
lethality) associated with allogeneic GVHD [104, 105].  Hongo et al. studied the role of 
NO during the early stages of GVHD induction (days -2 up to 14 post-BMT) and 
concluded that NO had a protective effect during this period since enhanced mortality 
was observed in mice when NO was inhibited by treatment with AG [106]. Similar 
results were obtained by Drobyski et al. in which inhibition of iNOS, with the 
administration of NG-methyl-L-arginine (L-NMA), after allogeneic BMT, resulted in 
significant decreased survival, likely due to decreased engraftment [98].   
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By itself, NO is a weak free radical but in combination with other ROS, like 
superoxide (O2-), it can result in the formation of peroxynitrite (OONO-), a very toxic and 
reactive product capable of mediating several cytotoxic processes [107](see Figure 1.3). 
Data presented in this dissertation will address the involvement of oxidative stress in the 
development of murine SGVHD and will be discussed in Chapter 3.  
1.7 Lymphocyte homing to inflammatory sites 
Homing of naïve lymphocytes from their site of origin, either bone marrow or 
thymus, into lymph nodes and peripheral tissues is governed by their lymphocyte 
trafficking  properties, which include tissue-specific adhesion and chemokine interactions 
[2, 108-113]. Migration into the inflamed gut requires lymphocyte trafficking through the 
mesenteric lymph nodes (MLN), an important site of the mucosal immune system [114]. 
Naïve T cells enter the MLN via high endothelial venules (HEV) and are able to 
encounter foreign antigens by their interaction with dendritic cells (DC) that resided in 
the intestinal tract and have processed gut-associated antigens, and transported them back 
to the MLN. As a consequence, these lymphocytes interact with these gut-antigen 
presenting DC,  become activated and express surface markers (i.e. L-selectin, α4β7) that 
change the migratory behavior of these activated effector cells. This acquired gut-homing 
phenotype enables them to reach the site of inflammation where they can exert their 
effect [2, 114, 115].  Proinflammatory chemokines, released by the tissue along with their 
corresponding receptors, found on active lymphocytes form an important axis that directs 
lymphocytes to the gut. Specific chemokines and their receptors, including CCL20, 
CCL5, CCR5, CCR6 among others, have been previously associated with inflamed 
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intestines observed in inflammatory bowel diseases (IBD) as well as murine models of 
colitis [111, 112].   
The recruitment of leukocytes from the vascular compartment into the 
extravascular space is crucial for the development of inflammatory responses. This 
movement involves cell adhesion interactions that are regulated by several ligands known 
as cell adhesion molecules (CAM) which are expressed in the surface of endothelial cells 
and leukocytes [110, 113, 116, 117]. Mucosal vascular addressins are tissue-specific 
endothelial cell adhesion molecules for circulating lymphocytes. They are expressed on 
the surface of vascular endothelial cells and serve as receptors to which ligands expressed 
on the surface of activated lymphocytes bind, thus allowing leukocyte homing to specific 
tissues [118]. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is an example 
of one of these vascular addressins that is expressed in mucosal endothelium lining blood 
vessels and serves to guide the entry of lymphocytes into mucosal lymphoid tissues such 
as the gut. MAdCAM-1 plays a critical role in mucosal immunity and is up-regulated 
during inflammation in the gut [116, 117]. It binds to integrin α4β7 expressed on the 
surface of activated T lymphocytes allowing their migration into the gut where they can 
initiate an inflammatory response [2, 116, 117]. It has been shown that lymphocytes 
expressing α4β7 migrate in a selective manner to sites of MAdCAM-1 expression [109]. 
Other examples of adhesion molecules include intercellular adhesion molecule-1 (ICAM-
1) and vascular adhesion molecule-1 (VCAM-1) which are both expressed on the 
endothelium and bind to integrins expressed on the surface of activated lymphocytes. 
Lymphocyte function-associated antigen-1 (LFA-1) is the ligand for ICAM-1 and has a 
major role in T cell activation and migration of both naïve and effector T cells out of the 
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blood. VCAM-1 binds to integrin α4β1, also known as VLA-4, thus allowing for the 
extravasation of effector T cells [2, 116]. It has been reported that TNF-α, and other 
proinflammatory mediators, can induce VCAM-1, ICAM-1 [119] and MAdCAM-1 upon 
inflammatory responses [120]. Oxidative stress induced by immune responses as a 
consequence of irradiation treatment and/or cytokine production can also induce CAM 
expression [121]. 
The interaction of blood lymphocytes with the endothelium involves multiple 
steps that account for their specificity. First, selectins on the T lymphocyte cells bind to 
sulfated carbohydrates on proteins such as vascular addressins (i.e. GlyCAM, ICAM-1, 
MAdCAM-1) that are expressed on endothelial cells. This allows for lymphocyte contact 
and weak interaction with the endothelium which initiates rolling of the lymphocyte 
along the endothelium surface. This step is crucial to initiate the cascade that leads to 
stronger interactions to allow for lymphocyte migration into the tissue. The second step 
consists of the actions of activating factors (i.e. chemokines), found in the environment, 
that bind to proteoglycan molecules on the endothelium walls and to receptors in the T 
lymphocyte cell, triggering rapid intracellular signaling in the leukocyte. This interaction 
leads to the activation of preexisting cell surface integrins (i.e. LFA-1, β7, α4) on the T 
cell that increases its affinity for cell adhesion molecule receptors (i.e. ICAM-1, 
MAdCAM-1, VCAM-1) which are expressed on endothelial cells, mediating firm arrest 
of the cell on the vessel wall. The interaction between receptor and counterligand allows 
for the fourth step known as diapedesis/extravasation in which the lymphocyte migrates 
through the vessel wall into the tissue [2](see Figure 1.4). The expression of these 
vascular addressin on the endothelium serves as a mark point to signal the presence of 
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infection attracting effector cells to the site of inflammation. Their interaction with 
integrins expressed on activated lymphocytes allows for the entry, in large numbers, of 
these effector cells into the infected tissue where they can conduct an inflammatory 
response. As increased numbers of CD4+ T cells were observed in the colon of CsA-
treated, BMT mice at the end of the SGVHD induction period, and the migration of these 
cells to the colon during this period was shown to be essential for the development of this 
disease [78], the data presented in Chapter 4 will examine the role of T cell homing into 
the gut at the early stages after BMT in the development of SGVHD.   
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Figure 1.1  CsA inhibition of the calcineurin signaling pathway in T cells 
Adapted from Steinbach et al. [122] 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  CsA inhibition of the calcineurin signaling pathway in T cells. Activation of 
T cell receptor (TCR) triggers increases in Ca2+ which activates calmodulin and allows its 
binding to calcineurin. The calcineurin catalytic subunit (A), when bound to the 
regulatory subunit (B) and calmodulin–Ca2+ complex, dephosphorylates nuclear factor of 
activated T-cells (NF-AT) in the cytoplasm, leading to nuclear migration of this 
transcription factor and the subsequent activation of various cellular processes. The 
dephosphorylation of NF-AT is inhibited by cyclosporine A (CsA) and FK506. 
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Figure 1.2  Nitric oxide generation from L-arginine oxidation 
Adapted from Vallance et al. [123] 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  Nitric oxide generation from L-arginine oxidation. For enzymatic activity, 
nitric oxide synthase (NOS) enzymes must dimerize and bind the cofactors 
tetrahydrobiopterin (BH4), haem, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD). On binding calmodulin (CAL), the active enzyme catalyses the 
oxidation of L-arginine to citrulline and nitric oxide (NO) and requires molecular oxygen 
and NADPH as co-substrates. Each NOS dimer coordinates a single zinc (Zn) atom. 
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Figure 1.3  Generation and detoxification of ROS/RNS 
Adapted from Griendling et al. [124] 
 
 
 
 
 
 
 
 
 
Figure 1.3  Generation and detoxification of ROS/RNS. Oxidases convert oxygen to 
superoxide (•O2⎯) which can react rapidly with nitric oxide (NO•) to form peroxynitrite 
(ONOO⎯) and cause downstream cellular damages. •O2⎯ can also be dismutated to 
hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 can be converted to 
H2O by catalase or glutathione peroxidase (GSH-Px) or to hydroxyl radical (•OH) after 
reaction with Fe2+.  
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Figure 1.4  Attachment of T cells to the endothelium and extravasation 
Adapted from Kunkel et al. [125]  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4  Attachment of T cells to the endothelium and extravasation. Integrins present 
on the surface of T cells mediate adhesion to the endothelium via their interaction with 
CAM. The multiple steps involved in T cells attachment to the endothelium includes: (1) 
tethering, (2) rolling, (3) adhesion and (4) diapedesis/extravasation. 
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CHAPTER TWO: MATERIAL AND METHODS 
2.1 Mice 
C3H/HeN mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN) 
at 20–21 days of age and were used within 1 week of arrival. The mice were given 
acidified water and fed autoclaved lab food ad libitum and were housed in sterile 
microisolator cages (Lab Products, Maywood, NJ). The animal used protocols were 
reviewed and approved by the University of Kentucky Institutional Animal Use and Care 
Committee.  
2.2 Induction of SGVHD 
Bone marrow (BM) was isolated from the femurs and tibias of syngeneic age-
matched mice. The donor BM suspensions were prepared in RPMI 1640 (Cellgro, 
Herndon, VA) supplemented with 5ml of penicillin/streptomycin/glutamine (100X; 
(Gibco-Invitrogen, Grand Island, NY)(see Appendix A for solution preparation). The 
resulting cell suspensions were resuspended in cytotoxic medium (RPMI 1640 containing 
penicillin/streptomycin/glutamine and 0.3% BSA Fraction V (Gibco-Invitrogen)) to a 
final concentration of 5 x 107 cells/ml.  BM cells were treated with monoclonal antibody 
(mAb) against Thy1.2 (HO-13-4, 1:20; American Type Culture Collection, ATCC No. 
TIB-99, Rockville, MD) to deplete Thy1+ cells, for 60 minutes on ice.  Anti-Thy1.2-
treated BM cells were then washed three times with cytotoxic medium and treated with a 
1:10 dilution of Low Tox-M rabbit complement (Cedarlane Laboratories, Westbury, NY) 
at a concentration of 5 x 107 cells/ml for 1 hour in 37°C water bath. After incubation, 
cells were washed three times with cytotoxic medium. Cell count was performed by 
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diluting cells 1:100 in cytotoxic medium with the adition of 5% acetic acid (Baxter; 
Stephens Scientific, Riverdale NJ, USA) then counted on a hemacytometer. The cell 
viability was determined by trypan blue exclusion. Removal of donor BM Thy1+ cells is 
required for disease development because in the presence of these autoregulatory cells 
development of SGVHD is reduced or inhibited depending on the strain of mice used 
[97]. Recipient mice were lethally irradiated with 900 cGy in a Mark I 137Cs irradiator 
(J.L. Shepard and Associates, Glendale, CA) 4-6 hours before transplant. Irradiated mice 
were reconstituted with 5 x 106 T cell-depleted BM cells (ATBM) intravenously (i.v.) in 
0.1 ml PBS via tail vein injection. Beginning on the day of transplantation, groups of 
mice were injected intraperitoneally (i.p.) daily for 21 days with 0.1 ml of either 15 
mg/kg CsA in the diluent olive oil (Sigma-Aldrich, St. Louis, MO) or diluent alone 
(Figure 2.1). CsA was purchased through the Division of Laboratory Animal Resources, 
University of Kentucky.  
2.3 Evaluation of SGVHD 
Following cessation of CsA, the animals were weighed three times per week and 
observed for clinical signs of the development of SGVHD (weight loss and diarrhea). 
Animals that lost weight for three consecutive weighings and/or diarrhea or mortality 
were considered as positive for the induction of SGVHD. In general, by 2–3 weeks after 
cessation of CsA therapy, clinical symptoms were evident (Figure 2.1) in approximately 
80% of the treated animals. Tissue samples were taken from the animals at different 
times during and post-CsA treatment. For histological evaluation of SGVHD, tissue 
samples taken from euthanized animals were immediately placed in 10% buffered 
formalin (Fisher Scientific, Atlanta, GA). Fixed tissues were embedded in paraffin, cut 
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into 4 to 6 µm tissue sections, mounted on glass slides, and then stained with a standard 
hematoxylin and eosin (H&E) procedure. All tissue sections were analyzed blind without 
the knowledge of the treatment category of the animal and graded for inflammation 
caused by SGVHD using a previously published grading scale [79] (Table 2.1).  
2.4  In vivo treatment with the antioxidant MnTBAP 
Mice were lethally irradiated, reconstituted with syngeneic ATBM and treated 
with either diluent or CsA as described. Treatment with MnTBAP was performed during 
or post-CsA therapy (Figure 2.2). MnTBAP reconstitution was performed following the 
manufacturer’s instructions (Axxora Life Sciences Inc., San Diego, CA.). The black 
crystalline powder was dissolved in 1 ml 0.1M NaOH, then 9 ml of 1X PBS was added to 
reach a final stock concentration of 5 mg/ml. The pH was adjusted to 7.4 and the solution 
was filter sterilized using a 0.2 µm syringe filter. The MnTBAP stock was stored in the 
dark at 4⁰C. For MnTBAP therapy during CsA period, treatment began two days prior to 
BMT when mice were treated i.p. with 10 mg/kg or 20 mg/kg of MnTBAP ending at day 
21 post-BMT. Twice a day dosing regimen was used based on the MnTBAP elimination 
half-time of 9.5 hours [126]. For post-CsA treatment, twice daily (10 mg/kg) antioxidant 
therapy began at day 21 post-BMT and was given for to 2-3 weeks.  Treatment was 
stopped when the majority of the CsA group (typically >80%) had developed SGVHD. 
Following cessation of MnTBAP therapy, the animals were monitored for the 
development of clinical symptoms of SGVHD as described.  
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2.5 In vivo neutralization of TNF-α 
To determine the effect of TNF-α on the induction of SGVHD, mice were treated 
with soluble TNF Receptor-1 (sTNFR-1) (Amgen, Thousand Oaks, CA) during the CsA 
treatment period (Figure 2.3). Four experimental groups were used in which mice 
received either olive oil, CsA alone, sTNFR-1 only or CsA and sTNFR-1. Several 
experiments were performed in which mice received sTNFR-1 beginning at different 
time points: (1) Two days prior to bone marrow transplantation; (2) At day three post-
BMT or (3) One week (day 7) post-BMT. The mice received 100 µg of sTNFR-1 i.p. 
beginning at the indicated times for 4 consecutive days and then every other day through 
day 21 post-BMT. Moribund animals were euthanatized and counted as mortalities. 
Animals were then monitored for clinical symptoms of SGVHD, as described previously.  
At the end of each experiment tissue was collected and analyzed for changes in immune 
parameters.  
2.6 Isolation of peripheral lymphoid cells 
At the indicated times after BMT, mice were euthanized by CO2 inhalation, the 
spleens were removed and placed into Stomacher bags (Fischer Scientific) containing 10 
ml 5% complete medium (RPMI 1640 containing penicillin/streptomycin/glutamine 
(Gibco), 5% FBS (Atlanta Biologicals, Inc., Norcross, GA, USA) and 5mM 2-
mercaptoethanol (2-ME) (Sigma Chemical Co.)). The tissue was homogenized in a 
Stomacher-80 (Fisher Scientific) to prepare single cell suspensions. The spleen cell 
suspensions were then treated with 0.83% Tris-buffered ammonium chloride (NH4Cl), 
pH 7.2, for 7 minutes at room temperature to lyse the red blood cells. Cells were then 
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washed once with 5% complete medium and the resulting cell population was diluted in 
0.04% trypan blue, counted on a hemacytometer and cell viability was determined by 
trypan blue exclusion. Isolated lymphoid cells were then stained following flow 
cytometry procedure described below. 
2.7 Treatment of lymphocytes with DCFH-DA 
Intracellular ROS were detected using the cellular marker 2’,7’-dichloro-
dihydrofluroscein diacetate (DCFH-DA) (Molecular Probes, Eugene, OR) following the 
method of Saito et al. with a slight modification [127]. Briefly, the lymphoid cells were 
isolated (2 x 106 cells/ml), washed once in 5% complete RPMI then resuspended in 
phosphate-buffered saline (PBS). The cells were incubated with DCFH-DA at a final 
concentration of 5 μM for 30 minutes at 37⁰C. Following incubation, the cells were 
washed twice in PBS and stained for surface markers following the flow cytometry 
method described below. 
2.8 Isolation of immune cells from the colon 
Intraepithelial lymphocytes (IEL) and lamina propia lymphocytes (LPL) were 
isolated according to a modification of the method of Lefrancois and Lycke [128]. Colons 
were removed from euthanatized mice at different times post- BMT and placed in Petri 
dishs containing cold calcium and magnesium free (CMF) HBSS (Ca2+ and Mg2+ free, 
100 mM HEPES (Sigma-Aldrich), 250 mM sodium bicarbonate (Fisher Scientific, 
Pittsburgh, PA), and 2% FBS (HyClone, Logan, UT)). The colons were cleaned by 
removing debris and all fecal matter. Tissue was cut open longitudinally and then 
laterally into ~0.5 cm pieces. Colon pieces were transferred into 50 ml conical tube 
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containing 40 ml cold CMF and kept on ice. Individual colons were pooled within the 
experimental groups and washed three times in cold CMF. Colon pieces were transferred 
into a sterile 125 ml Erlenmeyer flask and treated with 20 ml of 37⁰C CMF solution 
containing 1 mM dithiothreitol (DTT) (Research Products International, Mt. Prospect, IL) 
and 1 mM ethylenediamine tetraacetic acid (EDTA) (Sigma-Aldrich) and placed on a 
shaker for 30 minutes in a 37⁰C warm room. This step allows detachment of the epithelial 
cell layer. After incubation, contents of each flask were transferred to 50 ml conical 
tubes.  The tubes then were vortexed for 15 seconds and the supernatant containing cells 
was collected. CMF-DTT-EDTA was added to the tissue and the step was repeated twice 
combining the supernatant of both collections. The cell containing supernatant represents 
the epithelial fraction and contains the IEL. Tubes containing supernatant were 
centrifuged at 2000 rpm for 10 minutes. The supernatant was discarded and the cell pellet 
was washed once with 5% complete medium.  The IEL were resuspended in 10 ml cold 
10% complete medium (RPMI 1640 containing 10% FBS (Atlanta Biologicals, Inc.,) 
penicillin/streptomycin/glutamine (Gibco), and 5 mM 2-ME (Sigma)) and kept on ice 
while working with the LPL isolation. LPL suspensions were prepared by treating the de-
epithelialized intestinal tissue with 20 ml 10% medium containing 240U/ml collagenase 
(Sigma) and 2U/ml DNaseI (Roche, IN, USA) on a shaker for 1 hour at 37⁰C. This 
allows for further digestion of the tissue and the release of colonic LPL. Supernatant was 
then collected into 50 ml conical tubes and the step repeated twice collecting both 
supernatants containing the LPL. Tubes were then centrifuged at 2000 rpm for 10 
minutes. The supernatant was discarded and the cell pellet was washed once with 5% 
complete medium. The pellet containing the LPL was resuspended in 10 ml cold 10% 
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complete medium and kept on ice.  To enrich for T cells, the IEL and LPL suspensions 
were passed over a 0.2-g nylon wool (Robbins Scientific, Sunnyvale, CA) column and 
eluted with medium. The entire volume of eluate was collected in a 50 ml conical tube. 
Tubes were centrifuged at 2000 rpm for 10 minutes and pellet resuspended in 8 ml cold 
44% Percoll solution and kept on ice. First, 100% stock Percoll solution was made by 
diluting 90 ml Percoll (GE Healthcare Bio-Sceinces AB, Uppsala Sweden) with 10 ml of 
10X PBS. The appropriate volume of 100% Percoll solution was then added to 5% 
complete medium to make a 44% and 67% Percoll solutions. Lymphocytes were isolated 
by density percoll gradient centrifugation by overlaying the IEL and LPL in 44% Percoll 
solution over 14 ml polystyrene tubes containing 5ml cold 67% Percoll solution. Tubes 
were centrifuged at 1800 rpm for 30 minutes at room temperature. The cells in the 
44/66% Percoll interface were collected and transferred into a 50 ml conical tube. After 
collection the cells were washed once with cold 5% complete medium and resuspended 
in 2 ml of 10% complete medium. The resulting cell population was counted using 0.04% 
trypan blue exclusion and analyzed by flow cytometry, as described below. 
2.9 Flow cytometry analysis 
Isolated lymphoid cells (1 x 106) from the spleens and colons were placed into 
12x75 mm polystyrene tubes (Fisher Scientific) used for flow cytometry analysis and 
washed once using 2 ml of staining buffer (PBS containing 1% FCS and 0.1% NaN3). 
The staining buffer was poured off the cell pellet, leaving approximately 100 µl buffer in 
the tube. One µg Fc block, an antibody against CD16/CD32 (2.4G2; BD PharMingen, 
San Diego, CA) was added to each tube to reduce non-specific staining and incubated for 
15 minutes on ice. The appropriate labeled antibody (see Table 2.2) was added to the 
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tube to a final concentration of 1µg/tube and incubated on ice for 30 minutes. After 
incubation, the labeled cells were washed once with PBS containing 0.1% NaN3 (Sigma) 
and fixed with 1% paraformaldehyde (Sigma). Staining was analyzed using a BD 
Biosciences FACS Calibur flow cytometer (San Jose, CA) and 20,000-25,000 cells were 
analyzed per sample.  
2.10 Immunohistochemical staining 
To perform immunohistochemistry, tissue was placed in plastic cryostat holder 
(Sakura Tissue-Tek 4566, Cryomold Intermediate, Torrance CA, USA) embedded in 
Tissue-Tek Optimal Cutting Temperature (OCT) compound (Sakura Finetek, Torrance 
CA, USA), snap frozen in liquid nitrogen and stored in a -80⁰C freezer. Tissues were cut 
into 10-µm tissue sections, using a cyostat microtome instrument (Microm HM 505N) at 
-22⁰C, mounted on glass slides (Superfrost Plus Fisherbrand, Fisher Scientific, PA, USA) 
and stored in a -20⁰C freezer. Usually 4-6 slides per tissue was cut with each slide 
containing 2-3 tissue sections. At the time of staining, tissues were fixed in 3% 
paraformaldehyde for 15 minutes and washed three times with PBS for 5 minutes each. 
Slides were treated with blocking solution containing 2mg/ml normal donkey serum 
(Jackson ImmunoResearch, West Grove, PA), 0.3% Triton X-100 in PBS for 30 minutes 
at 4°C to block non-specific binding. All incubations were carried out in a dark 
humidifying chamber (Tupperware container with wet paper towel inside) to prevent 
drying.  After draining the excess blocking solution, slides were randomly selected for 
incubation with appropriate primary antibody (see Table 2.3) in PBS containing 2mg/ml 
normal donkey serum  and 0.3% Triton X-100 at 4⁰C overnight. After washing twice 
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with PBS for 30 minutes, sections were incubated with corresponding secondary antibody 
(see Table 2.3) for 1 h and then washed twice for 30 minutes. The MAdCAM staining 
required a third antibody (Strep-PE) and the procedure was performed following the 
exact same steps as staining with a secondary antibody. Control staining was performed 
by omitting the primary antibody during the procedure to control for the specificity of the 
primary antibody staining. Samples were visualized with a 100x objective and digitized 
with an AxioCam HR Vision System (Carl Zeiss MicroImaging Inc., Thornwood, NY). 
For each experiment, three to four animals were evaluated per experimental group and 
from each organ 4-5 fields were analyzed. 
2.11 Real Time Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR) for cytokine message 
Total colon and liver RNA was isolated using Trizol reagent (Invitrogen, Grand 
Island, NY). Briefly, samples were placed into RNA/DNAse-free 1.5 ml Eppendorf tubes 
(VWR International, LLC, Batavia, IL), homogenized in 1 ml of Trizol by hand using 
sample pestles (Reaserch Product International Corp., Mount Prospect, IL) and then 
incubated for 5 minutes at room temperature. After the tissue was homogenized, 200 µl 
of chloroform (Sigma St. Louis, MO) was added and the mixture was shaken vigorously 
by hand and using a vortex mixer (Fisher Scientific). Samples were then centrifuged at 
12,000 X g for 15 minutes at 4⁰C. The clear aqueous top layer was transferred into an 
RNA/DNAse-free 1.5 ml Eppendorf tube (VWR International, LLC) and 500 µl of 
isopropanol (Sigma) was added, to precipitate the RNA, and incubated for 10 minutes at 
room temperature. Tubes were then centrifuged at 12,000 X g for 10 minutes. The 
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supernatant was removed and the RNA pellet was washed with 1 ml 75% ethanol. 
Samples were vortexed and centrifuged at 7,500 X g for 5 minutes and the supernatant 
was discarded. The RNA pellet was resuspended in RNAse-free water, vortexed and 
stored in a -80⁰C freezer. The amount of RNA present in each sample was quantified by 
diluting 4 µl of RNA sample with 96µl of distilled water in a Quartz U.V. cuvette and 
reading the absorbance at 260 and 280 nm using a SmartSpecTM 3000 Spectrophotometer 
(Bio-Rad, USA). The A260:A280
 
ratio should be between 1.8-2.2 for pure RNA, values 
below this ratio may indicate the presence of co-purified contaminants. One µg of RNA 
from each group was reversed transcribed into cDNA using the Promega reverse 
transcription system (Madison, WI)(see Table 2.4, Panel A for procedure). The PCR 
reaction mixture was then prepared by combining 2.5 µl of cDNA with 10 µl of master 
mix (see Table 2.4, Panel B) and 1 µM of appropriate primer (see Table 2.5).  Real time 
RT PCR was performed on a Roche Lightcycler (Roche Diagnostics, Indianapolis, IN) 
and the amount of cytokine message was normalized to GAPDH and calculated by the 
comparative CT method.  
2.12  Measurement of serum NO 
Circulating nitric oxide (NO) levels were determined using a Cayman Chemical 
Nitrate/Nitrite Colorimetric Assay kit (Alexis Biochemicals, San Diego, CA). The 
reagents in this kit use nitrate reductase to reduce serum nitrate (NO3⎯) to nitrite (NO2⎯). 
To measure the production of NO during the induction of SGVHD (day 7-21 post-BMT), 
normal, control, and CsA-treated mice were euthanized individually by CO2 inhalation, 
and blood was obtained by cardiac puncture using a 25-gauge needle. The blood was 
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allowed to clot overnight at 4⁰C and the serum was collected. The serum samples were 
treated and assayed according to kit instructions. Briefly, samples were placed in 0.45 
µM Ultrafree-MC Centrifugal Filter Devices (Millipore Corporation, Bedford, MA)  and 
centrifuged for 2 minutes at 12,000 g using a accuSpin™ Micro (Fisher Scinetific) to 
remove interfering background absorbance attributable to proteins in the serum. After 
preparation of serum samples, nitrate in the samples was reduced to nitrite by incubation 
of 80 µl of sample with 10µl of Nitrate Reductase (Alexis Biochemicals) and 10 µl of 
Enzyme Cofactor (Alexis Biochemicals) at room temperature for 3 hours. All analyses 
were carried out in 96-well microtiter plates (Falcon, Becton Dickinson, Franklin Lakes, 
NJ) in triplicates. A nitrate standard curve was prepared by mixing 0.9 ml of Assay 
Buffer (Alexis Biochemicals) and 0.1 ml of reconstituted nitrite standard (in Assay 
Buffer; Alexis Biochemicals).  From this solution, eight dilutions were prepared to a final 
nitrite concentration of 0, 5, 10, 15, 20, 25, 30 and 35 µM. The plate was set up as follow, 
200 µl of Assay Buffer was added to blank wells, 100 µl of standard (for all eight 
dilutions) or 100 µl of serum was added to appropiate wells. The nitrate concentration in 
the samples was determined by the Griess reaction, by adding 50 µl of Griess reagent R1 
(sulphanilamide; Alexis Biochemicals), immediately followed by 50 µl of Griess reagent 
R2 (N-(1-Naphthyl) ethylenediamine; Alexis Biochemicals) to every well. The color was 
then allowed to develop for 10 minutes, at room temperature, before the absorbance was 
read at 540 nm using a Vmax microtiter plate spectrophotometer (Molecular Devices 
Corporation, Menlo Park, CA). A standard curve comparison was used to obtain the 
relative measurement of nitrite concentration for the serum samples. 
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2.13  SG6 cell line 
The SG6 cell line was established from peripheral lymphoid cells isolated from 
SGVHD mice exhibiting clinical symptoms of disease (typically 60-80% of CsA-treated 
animals). Animals were euthanized, the spleen and mesenteric lymph nodes were 
removed and placed into stomacher bags containing 5% complete medium. After 
homogenization, the single-cell suspensions of spleen and MLN were pooled and the 
RBC were removed with Tris ammonium chloride as described. CD4+ T cells were 
positively selected using CD4 (L3T4) mouse MicroBeads (MACS magnetic beads, 
Miltenyl Biotech, Auburn, CA, USA) with the cells being selected on an AutoMACS 
system (Miltenyl Biotech). The purity of the MACS-isolated donor cells was monitored 
by flow cytometry and found to be > 92% CD4+ T cells. Purified CD4+ T cells (1-2 x 
106), resuspended in 10% complete medium, were cultured in 24-well, flat-bottomed 
microtiter plates with 2 x 106 (2000cGy) irradiated cecal antigen-pulsed spleenic APC. 
The cecal antigen was prepared according to the procedure described by Cong et al. [81]. 
Briefly, the ceca were removed from animals and placed in a Petri dish containing PBS. 
The cecal contents were collected by low-speed centrifugation and were resuspended in 
PBS containing DNase I (10 µg/ml) (Sigma-Aldrich). Glass beads equal to 1/5th the 
volume of the material in the tube were added and the preparation was sonicated for 5 
min (15 s on, 15 s off) in a Fisher 550 Dismembrator (Thermo Fisher, Waltham, MA, 
USA). After sonication, the antigen preparation was centrifuged for 15 min at 10,000 rpm 
in a Fisher AccuSpin microcentrifuge (Thermo Fisher) to remove debris. The supernatant 
was removed, filter sterilized, and analyzed for protein content by Bio-Rad assay 
(Hercules, CA, USA). Spleen cells isolated from normal C3H/HeN mice were cultured 
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overnight with 200µg cecal antigens, washed, irradiated (2000 cGy) and utilized as 
described. After 8-10 days of culture the cells were harvested over lympholyte M 
(Atlanta Biologicals). The viable cells were counted and restimulated as described.  
2.14 Determination of Protein content using Bio-Rad assay 
Protein levels of cecal Ag preparation was measured by Bio-Rad assay following 
the standard protocol of the manufacturer. The Bio-Rad Dye reagent was prepared by 
diluting 1 part Dye Reagent Concentrate with 4 parts of distilled, deionized (DDI) water. 
The reagent was filtered using a Watman#1 paper to remove particulates. Dilutions were 
prepared for the bovine γ-globulin protein standard (1.38 mg/ml) and the sample as 
follow: four dilutions (690 µg/ml, 345 µg/ml, 173 µg/ml and 86.2 µg/ml) of the protein 
standard and eight dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256) of the cecal 
Ag preparation. One hundred (100) μl of each standard and sample solution was added 
into a glass test tube. Five ml of the diluted dye reagent was added to each tube and and 
the tubes were vortexed. The mixture was incubated at room temperature for 5 minutes. 
After incubation, the absorbance was measured at 595 nm using a SmartSpecTM 3000 
Spectrophotometer (Bio-Rad).  A standard curve comparison was used to obtain the 
relative measurement of protein concentration.  
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2.15 Labeling of SG6 cells with (CFSE) 
Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) according 
to the manufacturer’s instructions (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen, 
Eugene OR). Briefly, a 5 mM CellTrace™ CFSE stock solution was prepared by the 
addition of 18µl of DMSO (Sigma) to a vial of CFSE. SG6 cells were labeled by 
incubating 5 x 106 cells with 2.5 µM  CFSE in PBS for 6 min at 37⁰C. After incubation, 
the cells were washed once with 10% complete medium (RPMI 1640 containing 
penicillin/streptomycin/ glutamine and 10% FBS (Atlanta Biologicals, Inc., Norcross, 
GA, USA)). The cell pellet was diluted with 5 volumes of complete medium and the cells 
were further incubated for 15 minutes at 37°C to remove excess dye. The cells were 
washed with complete medium and resuspended in PBS for use in homing studies. 
2.16 In vivo homing of labeled SG6 cells 
The in vivo migration of SG6 cells labeled with CFSE was analyzed in several 
tissues of control and CsA mice at day 22 post-BMT. A total of 5 × 106 CFSE-labeled 
cells suspended in 0.1 ml of PBS were injected i.v. into tail vein of olive oil- or CsA-
treated mice at day 21 post-BMT. Mice were killed after 24 hours and the distribution of 
CFSE-labeled SG6 cells in different organs was measured. Tissues were removed from 
euthanized animals and immediately embedded in Tissue-Tek OCT compound and snap 
frozen in liquid nitrogen. Samples were cut into 10 µm tissue sections, mounted on glass 
slides and observed under a fluorescent microscope. Each labeled SG6 cell was counted, 
in 4-5 microscopic fields, over a 100x magnification. The mean values and their standard 
41 
 
error were determined from two independent experiments containing a total of four 
animals per experimental group. 
2.17 Statistics 
Statistical differences between experimental groups were determined using 
Student’s t test, Fisher’s exact test (induction) and Two way ANOVA analysis of 
variance. Differences p<0.05 were considered statistically different. 
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Figure 2.1  Induction of murine syngeneic graft-versus-host disease 
 
 
Figure 2.1  Induction of murine syngeneic graft-versus-host disease. C3H/HeN recipient 
mice were lethally irradiated (900 cGy) and reconstituted with 5 x 106 T cell-depleted 
bone marrow (ATBM) from syngeneic aged-matched mice. Beginning on the day of 
transplantation, mice were treated daily for 21 days with either 15mg/kg CsA in the 
diluent olive oil or with the diluent alone. Between 2-3 weeks post-CsA animals begin to 
develop clinical symptoms (weight loss and/or diarrhea).  
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Table 2.1 SGVHD Grading scale for colon and liver tissues 
Adapted from Bryson et al. [79] 
GRADING COLON LIVER 
+/- Rare crypt cell necrosis  Minimal lymphocyte infiltrate in 
portal area; rare bile duct epithelial 
cell degeneration 
1+ Definite scattered single-cell 
necrosis in crypts 
Sparse, but definite portal lymphocyte 
infiltrate; occasional necrotic bile duct 
epithelial cells 
2+ Several necrotic cells in 
gland, crypt abscesses present 
Diffuse infiltrate in portal area; 
invasion of bile ducts by inflammatory 
cells 
3+ Confluent destruction of 
glands 
Heavy infiltrate partially obscuring 
bile ducts; focal bile duct destruction 
4+ Loss of mucosa with 
formation of granulation 
tissue and pseudomembranes  
All the above plus secondary changes 
in hepatocytes, bile stasis, hepatocyte 
necrosis and disordered architecture 
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Figure 2.2   In vivo treatment with the antioxidant MnTBAP 
 
 
 
Figure 2.2  In vivo treatment with the antioxidant MnTBAP. C3H/HeN recipient mice 
were induced to develop SGVHD as described. Antioxidant treatment was performed 
either during or post-CsA therapy. For MnTBAP treatment during CsA period, mice were 
treated daily for 21 days with either 15mg/kg CsA in the diluent olive oil, the diluent 
alone, MnTBAP alone or CsA and MnTBAP. For MnTBAP treatment post-CsA, control 
or CsA-treated mice received MnTBAP starting at day 21 post-BMT for 2-3 weeks. 
Starting on day 21 post-BMT all mice are monitored for the onset of clinical symptoms 
(weight loss and/or diarrhea).   
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Figure 2.3  In vivo neutralization of TNF-α 
 
 
 
 
Figure 2.3  In vivo neutralization of TNF-α. C3H/HeN mice were induced to develop 
SGVHD as described previously. Groups of mice received either olive oil, 15mg/kg CsA, 
100 µg sTNFR-1 alone or CsA and sTNFR-1.  Neutralization of TNF- α started at several 
time points during the CsA treatment period. Mice were monitored for clinical symptoms 
of SGVHD (weight loss and/or diarrhea) starting on day 21 post-BMT. Tissue was 
collected at the end of each experiment for analysis.  
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Table 2.2  Antibodies used for flow cytometry analysis 
ANTIBODY SPECIFICITY LABEL MANUFACURER VOLUME 
ADDED 
Fc block Fc receptor None BD Pharmingena 1 µl 
F4/80  Macrophages APC BioLegenda 1 µl 
CD4 T cells APC Caltagb 1 µl 
αβ TCR FITC BD Pharmingena 2 µl 
CD62L Naïve 
phenotype 
PE BD Pharmingena 5 µl 
β7 integrin Activated 
lymphocyte 
FITC BD Pharmingena 1 µl 
CD44 Memory 
phenotype 
PE BD Pharmingena 5 µl 
a San Diego, CA; b Burlingame, CA 
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Table 2.3  Antibodies used for immunohistochemistry (IHC) analysis 
ANTIBODY SPECIFICITY LABEL MANUFACURER DILUTION 
Rabbit Anti-
nitrotyrosine 
Protein tyrosine 
nitration 
None Milliporea 1:50 
Goat Anti-
Rabbit IgG 
IgG heavy and 
light chains 
Oregon 
Green 488 
Invitrogenb 1:1000 
Mouse Anti-
MAdCAM-1 
MECA-367 None BD Pharmingenc 1:1000 
Anti-Rat IgG Rat IgG Biotin BD Pharmingenc 1:1000 
Streptavidin Biotin PE Sigmad 1:1000 
CD4 L3T4 FITC eBiosciencec 1:1000 
Anti-Rat IgG Rat IgG FITC eBiosciencec 1:1000 
a Temecula, CA; b Grand Island, NY; c San Diego, CA, d St. Louis, MO 
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Table 2.4  Real Time RT-PCR reaction conditions for mRNA analysis 
A. REVERSE TRANSCRIPTION REACTION* 
Reagenta Volume added per sample 
MgCl2 25mM 4.0 µl 
Buffer 10X pH.8.8 2.0 µl 
PCR Nucleotide Mix 10mM 2.0 µl 
Oligo (dT) 500µg/ml 1.0 µl 
RNasin 40U/µl 0.5 µl 
AMV Reverse Transcriptase 0.6 µl 
B. PCR REACTION (Master Mix) 
Reagent Volume added per sample 
Enzyme Diluentb 1.125 µl 
dNTPb 10X 2mM 1.250 µl 
Bufferb 10X w/BSA 30 mM MgCl2 1.250 µl 
Primerc 0.250 µl 
Sybr Greend 5X 0.625 µl 
dH2O 5.375 µl 
Platinum Taq DNA Polymerasee 5U/µl 0.125 µl 
cDNA 2.500 µl 
* After mixing all reagents, 1µg of RNA and dH2O to 20µl were added. The tubes were 
then incubated for 30 minutes at 42⁰C, then for 5 minutes at 95⁰C and 5 minutes on ice. 
Samples were stored in -20⁰C freezer.  
a Reagents were purchased from Promega Corporation (Madison, WI).  
b Reagents were purchased from Idaho technology Inc (Salt Lake City, UT). 
c  Reagents were purchased from Integrated DNA technologies (Coralville, IA). 
d  Reagents were purchased from Molecular probes (Eugene, OR). 
e  Reagents were purchased from Invitrogen (Grand Island, NY). 
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Table 2.5  Polymerase chain reaction (PCR) primers and conditions 
PRIMERS* SEQUENCE 
GAPDHa Forward 5’-TGCACCACCAACTGCTTA-3’ 
Reverse 5’-GGATGCAGGGATGATGTTC-3’ 
TNF-αa Forward 5’-CATCTTCTCAAAATT CGAGTGACAA-3’ 
Reverse 5’-TGGGAGTAGACAAGGTACAACCC-3’ 
iNOSa Forward 5’-TGACGGCAAACATGACTTCAG-3’ 
Reverse 5’-GCCATCGGGCATCTGGTA-3’ 
SOD-1a Forward 5’-AAGGCCGTGTGCGTGCTGAA-3’ 
Reverse 5’-CAGGTCTCCAACATGCCTCT-3’ 
GPxa Forward 5’-CCTCAAGTACGTCCGACCTG-3’ 
Reverse 5’-CAATGTCGTTGCGGCACACC-3’ 
CATa Forward 5’-GCAGATACCTGTGAACTGTC3’ 
Reverse 5’-GTAGAATGTCCGCACCTGAG -3’ 
MAdCAM-1a Forward 5’-GACACCAGCTTGGGCAGTGT-3’ 
Reverse 5’-CAGCATGCCCCGTACAGAG-3’ 
ICAM-1a Forward 5’-GGGACCACGGAGCCAATT-3’ 
Reverse 5’-CTCGGAGACATTAGAGAACAATGC-3’ 
VCAM-1a Forward 5’-CTGAATACAAAACGATCGCTCAA-3’ 
Reverse 5’-GCGTTTAGTGGGCTGTCTATCTG-3’ 
CCR5a Forward 5’-CAAGACAATCCTGATCGTGCAA-3’ 
Reverse 5’-TCCTACTCCCAAGCTGCATAGAA-3’ 
CCL5 b Forward 5’-TGCCCACGTCAAGGAGTATTT-3’ 
Reverse 5’-TCTCTGGGTTGGCACACACTT-3’ 
CCL20 c Forward 5’-CTGCTGGCTCACCTCTGCA-3’ 
Reverse 5’-CATCGGCCATCTGTCTTGTG-3’ 
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Table 2.5 (Cont.)  Polymerase chain reaction (PCR) primers and conditions 
 
* All the primers were purchased from Integrated DNA technologies (Coralville, IA). 
a 95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at  
  60⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes 
b 95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at  
  64⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes 
c  95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at  
  56⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes 
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CHAPTER THREE: ROLE OF OXIDATIVE STRESS IN SGVHD 
3.1 Synopsis 
Under normal  physiological conditions, the production of reactive oxygen species 
(ROS) as well as reactive nitrogen species (RNS) function as signaling molecules in 
many processes including cell cycle and metabolism [129, 130]. When the balance 
between levels of intermediate species is disrupted the harmful effects overcome the 
beneficial ones interrupting redox homeostasis. For this reason, there are several 
molecules that exist to counteract the damaging effects of oxidative stress and are known 
as antioxidants. This group of protective molecules include enzymes like superoxide 
dismutase (SOD), catalase and glutathione peroxidase (Gpx) [131]. Thus, oxidative stress 
production can be defined as the imbalance between the generation of free radicals, 
including their intermediates and the incapacity of antioxidant activity to reduce their 
effect. Recently, the concept of oxidative stress has been extended to not only ROS, like 
superoxide radicals and hydrogen peroxide but also includes RNS such as nitric oxide 
(NO), peroxynitrate and S-nitrosothiols [130]. Nitric oxide reacts with superoxide (O2-) to 
form peroxynitrite (ONOO-), a highly reactive species that induces nitrative and oxidative 
DNA damage [103, 107]. The role of oxidative stress in the pathophysiology of diseased 
states [88, 99, 126, 132]  has led to the development of metalloporphyrin catalytic 
antioxidants as possible therapeutic agents. Manganese (III) meso-tetrakis (4-benzoic 
acid) porphyrin (MnTBAP) is a stable metalloporphyrin that can scavenge a broad 
spectrum of reactive oxygen and nitrogen species [133-137]. This compound can 
scavenge peroxynitrite [137], catalyze the dismutation of superoxide [136] and hydrogen 
52 
 
peroxide [135], inhibit lipid peroxidation [134] as well as protect DNA from ROS-
mediated damage. MnTBAP has been successfully used to prevent oxidant-induced 
injury responses by activated macrophages both in vitro and in vivo [135, 136]. Since it 
has been implied that ROS is a mediator of CsA toxicity, and CsA treatment is a 
prerequisite for SGVHD induction, studies were undertaken to investigate the role of 
oxidative stress in the induction of SGVHD by treating mice with the antioxidant 
MnTBAP. Tissues from C3H/HeN mice were taken at various time points and analyzed 
for the presence of oxidative stress as well as proinflammatory cytokine expression and 
SGVHD induction. 
3.2 Determination of intracellular reactive oxygen species 
 Intracellular ROS production was determined by using the fluorescent probe 
DCFH-DA. When the diacetate form of DCFH (DCFH-DA) is added to cells, it diffuses 
across the cell membrane and is hydrolyzed by intracellular esterases to give 2’,7’-
dichlorofluorescin (DCFH), the oxidation of which yields fluorescent DCF [127] that can 
be monitored by flow cytometry. DCFH-DA labeled spleen cells were monitored, as an 
indicator of changes in ROS during SGVHD induction (days 0-21 post-BMT) (Figure 
3.1, A) as well as during the post-CsA period, when clinical symptoms of disease were 
evident (Figure 3.1, B). Oxidation of DCFH-DA to fluorescent DCF was significantly 
increased in CsA-treated animals by day 21 post-BMT (P=0.0240; Figure 3.1, A) as well 
as during active disease (P=0.0307; Figure 3.1, B) when compared to transplant control 
mice, demonstrating higher levels of ROS in CsA-treated animals. 
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3.3 Increased NO production in CsA-treated mice 
Since our data demonstrated elevated levels of ROS, we then decided to 
investigate if increases in RNS could also be detected during the development of 
SGVHD. Nitric oxide was particularly intriguing because of the relationship that had 
been identified between NO and gut pathology during allogeneic GVHD [105], as well as 
in the pathological processes that are associated with the development of murine SGVHD 
[100]. Real time RT-PCR studies were performed to determine if increases in mRNA for 
iNOS could be detected in the colon, one of the target organs of SGVHD, during the 
period of CsA therapy (Figure 3.2, A). Increased mRNA for iNOS was present in the 
colon of CsA-treated animals as early as day 14 (P=0.0262) and at day 21 post-BMT 
(P=0.0011). As previously published by our group [100], iNOS mRNA levels remain 
significantly elevated during active disease in colonic tissue of CsA-treated mice 
compared to BMT control (P=0.0146). Preliminary studies confirmed the PCR findings 
in that increases in circulating NO were observed in the plasma/serum of SGVHD mice 
relative to normal or transplant control animals (Figure 3.2, B). As another measure of 
oxidative stress in the tissues of CsA-treated/SGVHD animals we monitored protein 
tyrosine nitration since it is an important marker of oxidative stress induced by 
peroxynitrite and other nitric-oxide derived oxidants [99, 130]. Our results show 
increased nitrotyrosine in colonic tissue of CsA-treated mice compared to control mice by 
day 21 post-BMT (Figure 3.3, A) as well as during disease period (Figure 3.3, B), 
demonstrating increased oxidation mediated by peroxynitrite. Taken together, these 
results demonstrate that CsA-treated mice produced significantly elevated amounts of 
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RNS compared to control BMT mice and confirm that increased oxidative stress is 
generated in mice undergoing CsA therapy. 
3.4 Reduction of oxidative stress during CsA therapy alters the 
development of SGVHD 
To determine the role of conditioning-induced oxidative stress on the 
development of SGVHD, the antioxidant MnTBAP, a stable metalloporphyrin that can 
scavenge a broad spectrum of reactive oxygen and nitrogen species [133-137], was given 
to control BMT and CsA mice during the CsA therapy period. C3H/HeN mice were 
lethally irradiated, reconstituted with syngeneic BM and treated with CsA for 21 days as 
described. Beginning two days prior to BMT, the mice were treated with MnTBAP, 10 
mg/kg twice a day until day 21 post-BMT. Twice a day dosing regimen was performed 
based on the MnTBAP elimination half-time of 9.5 hours, as indicated by toxicology data 
[126]. Treatment of CsA mice with MnTBAP was able to significantly delay the 
induction of SGVHD in these animals compared to the ones that received CsA alone 
(Figures 3.4, A, B and C). Antioxidant therapy during CsA treatment delayed weight 
loss observed in the CsA-treated mice (Figure 3.4, A) as well as delayed development of 
clinical symptoms of SGVHD (P= 0.0023; Figure 3.4, B) and total disease induction (P= 
0.0240; Figure 3.4, C). 
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3.5 Decreased iNOS and TNF-α mRNA levels after MnTBAP therapy 
during CsA treatment 
Since the data showed increased levels of iNOS mRNA and RNS in CsA-treated 
animals compared to control BMT mice during CsA therapy (Figure 3.2), studies were 
undertaken to determine if treatment with the antioxidant MnTBAP was capable of 
reducing iNOS levels in CsA-treated animals during this time frame after BMT. Real 
time RT-PCR studies revealed a decrease in iNOS mRNA levels in CsA-treated mice that 
were treated with MnTBAP (10 mg/kg) at day 21 post-BMT (Figure 3.5, A), suggesting 
that MnTBAP therapy was able to reduce NO production by inhibiting the iNOS enzyme. 
Similarly, Garcia-Ruiz et al. recently demonstrated that iNOS activity was reduced 
following MnTBAP therapy in the murine model of non-alcoholic fatty liver disease 
(NAFLD) [138].  Additionally, TNF-α mRNA levels were analyzed since increased 
mRNA levels of this proinflammatory mediator in colonic tissue of CsA-treated mice 
were observed by day 21 post-BMT (refer to Chapter 4 of dissertation; Figure 4.3). 
MnTBAP therapy was able to decrease TNF-α mRNA levels in the colon of CsA-treated 
mice when compared to CsA mice that did not receive the antioxidant therapy (Figure 
3.5, B). While there was a clearly identified trend, the reduction in iNOS and TNF-α 
mRNA levels were not statistically significant (p≥0.05). The mRNA levels of the 
proinflammatroy cytokines IL-12 and IFN-γ, which are known to mediate SGVHD  [80, 
83] were also analyzed by real time RT-PCR at day 21 post-BMT and as shown in 
Figure 3.6, MnTBAP therapy did not reduce their levels in the colonic tissue of CsA-
treated mice. 
56 
 
3.6 Effect of MnTBAP treatment during CsA therapy on generation 
of oxidative stress 
 Our results demonstrated that treatment of CsA mice with an antioxidant reduced 
the severity of SGVHD when compared to mice receiving CsA alone. However, the 
mechanism(s) by which the SOD mimetic exerted its beneficial actions remained 
unknown. Given that the levels of nitrotyrosine in colonic tissue of CsA-treated mice 
were elevated when compared to transplanted controls (Figure 3.3), we analyzed the 
levels of this oxidative stress marker in control, CsA and CsA-MnTBAP treated mice at 
day 21 post BMT (Figures 3.7). Immunohistochemistry analysis revealed less 
nitrotyrosine staining in the colons of CsA mice that also received MnTBAP compared to 
mice treated with CsA alone (Figure 3.7, A). In addition, the quantitative measure of 
nitrotyrosine staining in colonic tissue revealed that MnTBAP treatment was capable of 
reducing oxidative stress in a significant manner when compared to mice that were only 
treated with CsA (Figure 3.7, B).  These studies demonstrated that treatment with the 
SOD mimetic reduced production of peroxynitrite in the colon of CsA-treated mice, 
reducing a potent RNS mediator that has been shown to be unregulated during intestinal 
inflammation of IBD [99]. 
3.7 Reduction of oxidative stress post-CsA therapy alters the 
development of SGVHD 
Since our results demonstrated that antioxidant therapy during the 21 days of CsA 
induction therapy was able to delay disease induction, we analyzed the role of oxidative 
stress post-CsA therapy in the development of SGVHD. For these experiments, treatment 
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with the antioxidant MnTBAP was given to BMT control and CsA mice after cessation of 
CsA therapy. C3H/HeN mice were lethally irradiated and reconstituted with syngeneic 
BM and treated with CsA for 21 days as described. Beginning on day 21 post-BMT, the 
mice were treated with MnTBAP 10 mg/kg twice a day for 2-3 weeks until CsA-treated 
mice were positive for SGVHD (≥ 80%). Treatment of control and CsA-treated mice with 
MnTBAP in the post-CsA period delayed the development of clinical symptoms of 
SGVHD (Figures 3.8, A, B and C). Antioxidant therapy post-CsA treatment reduced 
weight loss observed in the CsA-treated mice (Figure 3.8, A). Clinical symptoms of 
SGVHD, including weight loss, diarrhea and/or death were decreased in CsA-treated 
mice that also received MnTBAP compared to mice that did not receive the antioxidant 
therapy (P= 0.0050; Figure 3.8, B). In addition, total disease induction was significantly 
reduced by antioxidant therapy post-CsA period (P= 0.0003; Figure 3.8, C). Since iNOS 
mRNA levels were shown to be up-regulated during SGVHD (Figure 3.2), real time RT-
PCR analysis was performed to evaluate the effect that MnTBAP therapy had on the 
generation of iNOS mRNA at this stage of disease. Results showed decreased iNOS 
mRNA levels after antioxidant treatment in the colon of CsA-treated mice if compared to 
mice that received CsA alone (Figure 3.9). In addition, MnTBAP treatment in the post-
CsA period was also capable of reducing nitrotyrosine staining in CsA-treated mice as 
shown in Figure 3.10.  These results were not surprising as our group had previously 
shown that inhibition of iNOS post-CsA therapy decreased SGVHD induction [100].  
Interestingly, histological analysis of colonic tissue revealed that MnTBAP treatment 
post-CsA therapy did not ameliorate disease pathology observed in CsA-treated mice 
(Figure 3.11) and was confirmed by immunohistochemistry analysis of CD4+ T cells in 
58 
 
which migration of these effector cells into the colon of CsA-treated mice was not 
decreased by antioxidant therapy (Figure 3.12). 
3.8 Summary 
The results presented in this chapter confirm the hypothesis that SGVHD 
induction results in increased oxidative stress in CsA-treated mice compared to BMT 
controls. Treatment with a commercially available SOD mimetic, MnTBAP, during the 
21 days of CsA therapy as well as post-CsA period resulted in delayed disease induction 
and clinical symptoms of SGVHD. However, the reduction of proinflammatory mediators 
and oxidative stress was not enough to completely ameliorate disease induction.  
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Figure 3.1  Elevated ROS in mice treated with CsA compared to control BMT 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Elevated ROS in mice treated with CsA compared to control BMT. Spleen 
cells from CsA-treated mice produce increased levels of DCFH-DA. Spleens were 
removed from control and CsA-treated mice at day 21 post-BMT (A) or during active 
disease (B). Splenocytes were isolated and treated with DCFH-DA, as described and 
analyzed by flow cytometry.  Data presented is pooled from four individual experiments, 
n represents the number of animals per group. 
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Figure 3.2  Increased reactive nitrogen species in CsA-treated mice 
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Figure 3.2  Increased reactive nitrogen species in CsA-treated mice. (A) Increased levels 
of iNOS mRNA in CsA-treated mice. Animals were induced to develop SGVHD as 
described. Tissue isolated from the colon at several time points was analyzed by real time 
RT-PCR. Data is representative of two experiments with n representing the number of 
mice. (B) Circulating NO is increased in CsA-treated animals. Normal, control, and CsA-
treated BMT recipient mice were bled at several time points during CsA therapy. Serum 
was collected, and nitrate was reduced to nitrite by nitrate reduction and analyzed for the 
presence of NO2⎯. Data is representative of one experiment.  
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Figure 3.3  Increased levels of nitrotyrosine in the colons of CsA-treated mice 
 
 
Figure 3.3  Increased levels of nitrotyrosine in the colons of CsA-treated mice compared 
to transplant controls. Colon tissue was isolated at day 21 post-BMT (A) and during 
SGVHD (B) and frozen sections analyzed for the presence of nitrotyrosine, a marker of 
RNS by IHC analysis. Slides were visualized under 100x magnification. The data 
presented are representative of samples from four mice from two individual experiments. 
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Figure 3.4  MnTBAP treatment delayed the development of SGVHD 
A.  Antioxidant therapy reduced weight loss in CsA mice 
 
 
 
 
 
 
 
B.  Delayed disease induction in MnTBAP treated mice 
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Figure 3.4 (Cont.) MnTBAP treatment delayed the development of SGVHD 
C. Decreased SGVHD total induction after MnTBAP therapy 
 
 
 
 
 
 
Figure 3.4  MnTBAP treatment delayed the development of SGVHD. Disease was 
induced in C3H/HeN mice, as described. Groups of control or CsA-treated mice were 
given 10 mg/kg of MnTBAP twice a day starting 2 days prior to BMT and every day for 
21 days. The animals were then monitored for SGVHD induction (weight loss, diarrhea 
and/or mortality). (A) Animals were weighed individually 3x per week starting on day 21 
post-BMT. Data presented represent pooled data from 2 experiments, plotted as average 
± SEM of percent weight change for each treatment group (n = 16); (B) Animals were 
followed for induction and plotted as average ± SEM for the time to induction after BMT. 
Data presented represent pooled data from 4 experiments (n = 16); (C) Analysis for 
induction measured 49 days post-BMT, with the number of animals with SGVHD/total 
number of animals within each group presented above each bar. Data presented are 
pooled from four experiments. 
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Figure 3.5  MnTBAP therapy resulted in decreased colonic iNOS and TNF-α 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  MnTBAP therapy resulted in decreased colonic (A) iNOS and (B) TNF-α. 
C3H/HeN mice were induced for SGVHD and treated with MnTBAP as described. On 
the day after the last MnTBAP treatment, the colon was removed from control, CsA-
treated, MnTBAP-control, and MnTBAP-CsA-treated animals. Messenger RNA was 
isolated and analyzed by real time RT-PCR. Data presented are pooled from three 
individual experiments, n represents the number of mice per group.   
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Figure 3.6  MnTBAP therapy did not reduce IL-12 or IFN-γ mRNA levels 
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Figure 3.6  MnTBAP therapy did not reduce IL-12 or IFN-γ mRNA levels. SGVHD was 
induced as described and mRNA was isolated from the colons of control, CsA, MnTBAP 
and CsA+MnTBAP treated animals at day 21 post-BMT. Real time RT-PCR was 
performed for IL-12 (A) and IFN-γ (B). Data presented are the mean ± SEM, from 
pooled samples of four independant experiments, n represents the number of mice per 
group.   
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Figure 3.7  Reduced nitrotyrosine staining after antioxidant therapy 
A. Immunohistochemistry staining of nitrotyrosine at day 21 post-BMT 
 
 
B. Quantitative measure of nitrotyrosine staining on day 21 colonic tissue 
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Figure 3.7  Reduced nitrotyrosine staining after antioxidant therapy. Colons of C3H/HeN 
mice were removed at day 21 post-BMT and frozen sections were analyzed by 
immunohistochemistry techniques for the presence of nitrotyrosine (A). Slides were 
visualized under 100x magnification and staining per field was quantified (B). The data 
presented are representative of samples from four mice from two individual experiments. 
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Figure 3.8  Delayed SGVHD after MnTBAP treatment post-CsA 
A. Antioxidant therapy reduced weight loss in CsA mice 
 
 
 
 
 
 
 
 
 
 
B. Delayed disease induction in MnTBAP treated mice 
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Figure 3.8 (Cont.) Delayed SGVHD after MnTBAP treatment post-CsA 
C. Decreased SGVHD total induction after MnTBAP therapy 
 
 
 
 
 
 
 
Figure 3.8  Delayed SGVHD after MnTBAP treatment post-CsA. Disease was induced 
in C3H/HeN mice, as described and groups of control or CsA-treated mice were given 10 
mg/kg of MnTBAP twice a day beginning on day 21 post-BMT and every day up to 2-3 
weeks, when the majority (> 80%) of the CsA animals had developed SGVHD. Animals 
were monitored for clinical symptoms of SGVHD. (A) Animals were weighed 
individually 3x per week starting on day 21 post-BMT and plotted as average ± SEM of 
percent weight change for each treatment group. (B) Animals were followed for 
induction and plotted as average ± SEM for the time to induction after BMT. (C) 
Analysis for induction measured 43 days post-BMT, with the number of animals with 
SGVHD/total number of animals within each group presented above each bar. Data 
presented are pooled from two experiments. Control n = 9, CsA n = 15, MnTBAP n = 12 
and CsA+MnTBAP n = 16. 
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Figure 3.9  MnTBAP therapy reduced mRNA levels of iNOS 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 3.9 MnTBAP therapy reduced mRNA levels of iNOS. C3H/HeN mice were 
induced for SGVHD, as described and treated with MnTBAP post-CsA therapy. On the 
day after the last MnTBAP treatment, the colon was removed from each experimental 
group and mRNA was isolated from the colonic tissue. Real time RT-PCR was 
performed for iNOS. Data presented are pooled from two independent experiments, n 
represents the number of animals analyzed. 
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Figure 3.10  Decreased RNS in colon of CsA-treated mice after MnTBAP therapy 
A. Immunohistochemistry staining of nitrotyrosine at day 21 post-BMT 
      
  
 
B. Quantitative measure of nitrotyrosine on SGVHD mice 
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Figure 3.10 Decreased RNS in colon of CsA-treated mice after MnTBAP therapy. 
Immunohistochemistry analysis of colonic tissue during diseased stage revealed 
increased nitrotyrosine staining in colons of CsA-treated mice compared to control BMT 
and reduced staining in CsA after antioxidant therapy (A). Quantification of nitrotyrosine 
staining (B). Data is pooled from 2 experiments and represents n=4 mice per group. 
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Figure 3.11  Colon pathology was not altered by MnTBAP treatment 
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Figure 3.11 Colon pathology was not altered by MnTBAP treatment. Histological 
examination of SGVHD colons shows no difference after antioxidant therapy. Colon 
tissue was isolated during clinical symptoms of SGVHD, typically 3–4 weeks post-CsA 
treatment. The tissues were stained using H&E staining procedure and pathology grading 
was performed as described in Materials and Methods. Data represents mean grade ± 
SEM, n represents the number of mice per experimental group pooled from two 
independent experiments.  
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Figure 3.12  Migration of T cells into the colon was not reduced by MnTBAP 
    
 
Figure 3.12 Migration of T cells into the colon was not reduced by MnTBAP. 
Immunohistochemistry staining of CD4+ T cells in colonic tissue of SGVHD mice. Colon 
tissue from control BMT, CsA and CsA-MnTBAP treated animals was collected at day 
43 post-BMT and frozen sections were stained for the presence of CD4+ T cells. Colons 
from CsA animals show increased levels of CD4 staining compared to control BMT but 
MnTBAP treatment had no effect on inhibiting T cell migration into the colon of CsA-
treated mice. The data presented are representative of n=4 from two individual 
experiments. 
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CHAPTER FOUR: ROLE OF T CELL HOMING IN SGVHD 
 
4.1  Synopsis 
Histological studies have demonstrated severe colonic tissue damage in SGVHD 
mice caused by massive infiltration of inflammatory cells, particularly CD4+ T cells, into 
the colon of CsA-treated mice [55, 78, 80, 83, 100, 139]. Bryson et al. demonstrated a 
role for CD4+ T cells in the induction of colitis observed in murine SGVHD. Increased 
CD4+ but not CD8+ T cells were observed in the colons of diseased animals. 
Additionally, in vivo depletion of CD4+ T cells during CsA therapy inhibited significantly 
the induction of SGVHD [78] and SGVHD can be adoptively transferred with CD4+ T 
cells from diseased animals into secondary recipients [58]. Previously published studies 
have demonstrated that an increase in colonic CD4+ T cells was observed in CsA-treated 
mice by day 21 post-BMT, suggesting that enhanced T cell migration into the colon 
occurred during the CsA treatment period [78]. Studies were then undertaken to follow 
the migration of T cells at the early stages after BMT and investigate the mechanism that 
could result in the increased intestinal migration of CD4 effector T cells during the 
induction of SGVHD. Tissues from C3H/HeN mice were taken at various time points 
during CsA treatment and analyzed for the presence of CD4+ T cells, CAM, chemokines 
and proinflammatory cytokines associated with T cell homing into the gut. In vivo studies 
were performed using a CFSE-labeled SGVHD CD4+ T cell line to investigate where 
these T cells preferentially migrate. These investigations allowed us to gain a better 
understanding of the functional mechanisms that take place, during the 21 days of 
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induction/immunosuppression therapy, that result in the increased homing of effector T 
cells into colons of CsA-treated mice. 
4.2  Enhanced CD4+αβTCR+ T cells in colons of CsA-treated mice 
compared to control BMT 
Previous studies have shown significant increases in colonic CD4+ T cells isolated 
from SGVHD mice at 2–4 weeks post-CsA (5–7 weeks post-BMT) relative to transplant 
control animals [78]. In addition, a 2-fold increase in CD4+ T cells was also observed in 
the IEL isolated from CsA versus BMT control mice 21 days after transplant, at the end 
of CsA therapy [78].  These studies suggested that increased numbers of CD4+ T cells 
migrated into the colon of CsA-treated mice during CsA therapy. Studies were therefore 
initiated to follow the migration of T cells into the colon during the CsA treatment period 
(days 0-21 post-BMT). For these experiments, colons were isolated from control and 
CsA-treated mice at several time points during the 21 days of CsA therapy and the IEL 
and LPLs were isolated and analyzed by flow cytometry for various T cell markers. As 
shown in Figure 4.1, A an increased percentage of CD4+αβTCR+ T cells was found in 
the colons of CsA-treated mice as early as day 14 post-BMT (P=0.0288) and they 
maintained this increase through day 21 post-BMT (P=0.0001). Lamina propia 
lymphocytes isolated from CsA versus control also showed an increased percent of 
CD4+αβTCR+ T cells as well (Figure 4.1, B). Intraepithelial lymphocytes and LPL were 
also analyzed during active disease and confirmed previous results in which SGVHD 
mice had increased infiltration of CD4+ T cells into their large intestine compared to 
control BMT animals (Fig 4.1, A, B). Immunohistochemistry analysis was performed to 
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confirm the flow cytometry analysis of isolated cells. In situ analysis demonstrated 
increased CD4+ T cell staining in the colonic tissue of CsA-treated mice compared to 
control BMT at days 14 and 21 post-BMT (Figure 4.2).  
4.3  Increased proinflammatory mediators and cell adhesion 
molecules (CAM) during SGVHD 
Total body irradiation (TBI) can affect the severity of many diseases by 
amplifying the dysregulation of inflammatory cytokines. Irradiation along with allogeneic 
immune cells can damage the gastrointestinal (GI) tract, which allows for increased 
translocation of lipopolysaccharide (LPS) into the systemic circulation leading to 
increased levels of TNF-α [140]. Radiation has also been shown to stimulate macrophage 
production of proinflammatory cytokines in a dose dependant manner [141]. Using the 
murine model of SGVHD, Bryson et al. observed a significant increase in the migration 
of CD4+ T cells into colons of CsA-treated animals during active disease [78]. Several in 
vivo and in vitro studies have demonstrated that endothelial cells (EC) respond to stimuli 
such as irradiation, LPS and TNF-α by either becoming activated or undergoing apoptosis 
[140, 142]. Additionally, early interactions between allogeneic lymphocytes and vascular 
endothelial cells correlate with up-regulated mRNA levels of adhesion molecules, as well 
as TNF-α, which can result in lymphocyte adherence and EC injury [143]. TNF-α is an 
inflammatory cytokine capable of inducing cell adhesion molecules such as VCAM-1, 
ICAM-1[119] and MAdCAM-1 [120]. Studies were therefore designed to examine the 
levels of adhesion molecules, TNF-α and proinflammatory chemokines in colonic tissue 
of CsA and control BMT mice. Real time RT-PCR assays were performed to determine if 
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increases in mRNA for TNF-α and CAM could be detected in the colon of CsA-treated 
animals. Results from a time course study revealed significantly increased mRNA levels 
for TNF-α at days 14 and 21 post-BMT in colonic tissue of CsA mice compared to BMT 
control (P=0.0009 at day 14 post-BMT; P=0.0387 at day 21 post-BMT; Figure 4.3).  
Concomitant with this increase in proinflammatory cytokine production, colons of 
CsA mice had increased mRNA levels of CAM as early as day 14 post-BMT compared 
to control mice (Figure 4.4). MAdCAM-1 mRNA analyzed by real time RT-PCR 
revealed significantly increased levels at days 14 and 21 post-BMT in CsA-treated mice 
compared to BMT control mice (P=0.0358 at day 14; P=0.0006 at day 21 post-BMT 
Figure 4.4, A). Similar results were observed for VCAM-1 (P=0.0179 at day 14; 
P=0.0478 at day 21 post-BMT Figure 4.4, B) and ICAM-1 (P=0.0347 at day 14; 
P=0.0070 at day 21 post-BMT Figure 4.4, C). Immunohistochemistry staining of 
MAdCAM-1 expression confirmed the elevated levels of CAM in colonic tissue of CsA-
treated mice. Increased levels of MAdCAM-1 were observed as early as day 14 post-
BMT in colons of CsA-treated mice compared to control BMT and this expression was 
sustained during the time course study up to the period of active disease for SGVHD 
(Figure 4.5). 
Chemokines play an important role in lymphocyte trafficking to specific sites, 
regulating immune responses and homeostasis. Radiation therapy is capable of disrupting 
the epithelial integrity leading to an inflammatory response and hence increased 
expression of proinflammatory cytokines and chemokines [140, 142, 144]. The 
constitutive presence of these regulators allows for the trafficking of lymphocytes into the 
gastrointestinal mucosal compartment disrupting the physiological balance and 
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contributing to pathogenesis like inflammatory bowel diseases (IBD) [111, 112]. Since 
many studies have confirmed increases in proinflammatory chemokines (i.e. CCL20, 
CCR6, CCR5, CCL5) during gut inflammation [111-113], experiments were performed 
to investigate if chemokines associated with mucosal homing were up-regulated during 
CsA treatment. Figure 4.6 shows significant increases in mRNA levels of CCL20 
(Figure 4.6, A; p=0.0089), CCR5, its ligand CCL5 (Figure 4.6, B; p=0.0150 and Figure 
4.6, C; p=0.0406) and its ligand CCL3 (data not shown), in the gut of CsA-treated mice 
compared to controls at day 21 post-BMT. This significant increase in mediators and 
ligands were present in CsA-treated versus control BMT mice, suggesting a role for these 
molecules in the enhanced migration of CD4+ T cells into the colon of CsA-treated 
animals. 
4.4  Increased homing of labeled SGVHD T cells into the colons of 
CsA-treated mice 
An increase in the migration of CD4+ T cells was observed into the colons of 
CsA-treated mice compared to control BMT as early as day 14 post-BMT and this 
increase correlated with an increase in CAM and chemokines associated with mucosal 
homing.  Studies were undertaken to determine if increases in these molecules was 
indeed functional. Since increased homing of CD4+ T cells were observed in the colonic 
tissue of CsA-treated mice, along with increased β7 integrin expression (preliminary 
data), we hypothesized that the most likely CAM involved in the trafficking of these 
lymphocytes to the gut is MAdCAM-1, which has been previously implied to be up-
regulated in gut inflammation [109, 116]. For these experiments, a long term microbial 
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Ag-specific CD4+ T cell line isolated from SGVHD animals was used to study the 
homing of lymphocytes into several organs of control and CsA-treated mice. 
Phenotypically the CD4+ T cell line (SG6) was β7 integrin+ (Figure 4.7) and had an 
activated phenotype (CD62L⎯, CD44hi; data not shown). Stimulation of the SG6 cells 
with APC pulsed with bacterial Ag resulted in a significant proliferative response 
compared to APC alone (Figure 4.8). Similar responses have been observed in primary 
CD4+ T cells isolated from SGVHD mice compared to those from BMT control animals 
[58]. To determine if these CD4+β7integrin+ SGVHD T cells would migrate at a higher 
frequency to the colon of CsA-treated mice versus that of control animals, SG6 cells 
labeled with CFSE were injected i.v. into the tail of control and CsA-treated mice at day 
21 post-BMT. At this time point post-BMT increased expression of CAM and 
chemokines is present in CsA-treated mice (Figures 4.4-4.6). Tissues were isolated 24 h 
after SG6 injection and analyzed by fluorescent microscopy. Increased levels of SG6-
labeled cells migrated into the colons of CsA-treated mice compared to control BMT 
(Figure 4.9, A). Similar increases in migration were also observed in the liver as well 
(data not shown). When the number of labeled SG6 were enumerated, a significant 
increase in the migration of these labeled CD4+ T cells into the colonic tissue of mice 
treated with CsA (P=0.0038) was observed compared to control BMT animals (Figure 
4.9, B), supporting the observation that increases in CAM were functional for the 
migration of CD4+ T cells observed in the colons of CsA-treated mice.  
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4.5 CD4+ T cell migration into the liver 
 The liver, along with the colon, represent the main target organs affected by the 
development of murine SGVHD. Histological evaluation of tissue samples from SGVHD 
mice have demonstrated increased lymphocytic infiltration of the colon and liver of CsA-
treated compared to control BMT animals. Studies from this laboratory have 
demonstrated that there was a 100% correlation between liver and colon inflammation. In 
addition, the adoptive transfer of CD4+ T cells from SGVHD mice into secondary 
recipients, not only resulted in colon pathology, but liver inflammation as well that was 
identical to de novo SGVHD [58]. The chronic liver inflammation that occurs during the 
development of murine SGVHD is very similar to that observed during the early stages of 
primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis is a chronic 
inflammatory process of intra- and extra-hepatic bile ducts [145-147] and has been 
frequently associated with inflammatory bowel disease (IBD) [148, 149]. In addition, 
expression of MAdCAM-1 and CCL25, which are typically restricted to the endothelium 
of the gut mucosa have been shown to be upregulated on the portal endothelium of the 
liver, allowing the recruitment of α4β7+, CCR9+, CD4+ memory T cells to the liver from 
the gut [150]. Given the similarities between IBD, SGVHD and chronic liver 
inflammation, preliminary studies were initiated to monitor CD4+ T cell migration into 
the livers of control BMT and CsA-treated animals. Immunohistochemistry analysis of 
liver samples at several time points after BMT revealed that while these CD4+ T cells are 
observed as early as day 14-post BMT in the colon of CsA mice (Figure 4.2),  they are 
not present in the liver until active disease (Figure 4.10). Furthermore, mRNA analysis 
of liver samples for MAdCAM-1 at day 14 post-BMT revealed no difference between 
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CsA and control mice, but a slight increase at day 21 pos-BMT (Figure 4.11) and 
significant difference during active disease (data not shown). In addition, as stated above, 
similar to murine colitis models, our results have demonstrated enhanced responsiveness 
of SGVHD CD4+ T cells against antigens isolated from cecal bacterial preparations. 
These studies suggest that there is an ordered migration of T cells reactive against 
bacterial antigens from the gut into the liver during the development of SGVHD.  
4.6  Summary 
  The data in this chapter represents the first demonstration that the CD4+ T cells 
responsible for the pathogenesis observed in murine SGVHD are increased as early as 
day 14 post-BMT in the colons of CsA-treated mice compared to BMT controls, 
suggesting that during the 21 days of immunosuppressive therapy these CD4+ T cells are 
either migrating or expanding into the intestines of these animals in a CsA-resistant 
manner. Concurrent with these findings, elevated expression of CAM, chemokines and 
proinfllammatory cytokines, shown to be involved in gut inflammation, were also 
elevated in the colon of CsA-treated mice. Finally, in vivo homing studies using CD4+ T 
cells from SGVHD animals confirmed increased migration of these effector cells into the 
colon of CsA-treated mice, suggesting a functional role for the increased CAM 
expression observed in CsA-treated animals. 
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Figure 4.1  Enhanced numbers of CD4+ IEL and LPL isolated from CsA-treated animals      
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Figure 4.1  Enhanced numbers of CD4+ IEL and LPL isolated from CsA-treated animals. 
C3H/HeN mice were lethally irradiated, reconstituted with syngeneic BM and treated for 
21 days with 15 mg/kg of CsA i.p. At times after BMT, colons from mice were isolated 
and pooled within each experimental group. After isolation, (A) IEL and (B) LPL cells 
were stained with mAb for CD4 and αβTCR and analyzed by flow cytometry. Data is 
presented as the mean ± SEM, with n representing the number of experiments performed. 
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Figure 4.2  Elevated CD4 expression in colonic tissue of CsA-treated mice compared to 
control BMT 
 
 
Figure 4.2 Elevated CD4 expression in colonic tissue of CsA-treated mice compared to 
control BMT. Immunohistochemistry staining revealed increased CD4+ T cells in colonic 
tissue of CsA-treated mice. Colon tissue from control BMT and CsA animals was 
collected at several time points (Days 14, 21 and 37) and frozen sections were stained for 
the presence of CD4+ T cells. Colons from CsA animals (top panel) show increased 
levels of CD4 staining compared to control BMT (lower panel). The data presented are 
representative of n=6 from two individual experiments. 
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Figure 4.3  Increased production of TNF-α in colonic tissue of CsA-treated mice 
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Figure 4.3 Increased production of TNF-α in colonic tissue of CsA-treated mice. 
C3H/HeN mice were induced for SGVHD as described. Tissue isolated from the distal 
colon was taken at the indicated time points during CsA treatment and analyzed by real 
time RT-PCR for the presence of mRNA for TNF-α. Data presented are the mean ± SEM, 
with n representing the number of animals analyzed in each group pooled from two 
independent experiments. 
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Figure 4.4  Elevated levels of CAM mRNA in the colon of CsA-treated mice compared 
to control BMT 
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Figure 4.4 (Cont.). Elevated levels of CAM mRNA in the colon of CsA-treated mice 
compared to control BMT 
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Figure 4.4  Elevated levels of CAM mRNA in the colon of CsA-treated mice compared 
to control BMT. RNA was isolated from the colons of control BMT and CsA-treated 
animals at the indicated time points. Real time RT-PCR was performed for (A) 
MAdCAM-1, (B) VCAM-1 and (C) ICAM-1. Data represents pooled results of two 
experiments and is shown as the mean ± SEM, with n representing the number of animals 
analyzed in each group. 
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Figure 4.5  Increased presence of MAdCAM-1 in colonic tissue of CsA-treated mice 
compared to control BMT 
 
 
 
Figure 4.5  Increased presence of MAdCAM-1 in colonic tissue of CsA-treated mice. 
Colon tissue was isolated at days 7, 14, 21 and 37 after BMT, snap frozen and sections 
from control BMT and CsA-treated mice were stained by immunohistochemistry 
techniques for the presence of MAdCAM-1 (100x). The data presented are representative 
of n=9 from three independent experiments. 
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Figure 4.6 SGVHD induction results in increased production of proinflammatory 
chemokines in the colon 
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Figure 4.6 (Cont.) SGVHD induction results in increased production of proinflammatory 
chemokines in the colon 
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Figure 4.6  SGVHD induction results in increased production of proinflammatory 
chemokines in the colon. Messenger RNA was isolated from the colons of control BMT 
and CsA animals at day 21 post-BMT. Real time RT-PCR was performed for CCL20 (A), 
CCR5 (B) and CCL5 (C). Data presented are the mean ± SEM, from pooled samples 
from 2 experiments, with n=6. 
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Figure 4.7  SGVHD T cell line express a CD4+β7integrin+ phenotype 
 
   
 
 
Figure 4.7  SGVHD T cell line express a CD4+β7integrin+ phenotype.  SGVHD T cell 
line or SG6 was harvested over Ficoll and analyzed by 2-color flow cytometry for CD4 
and  β7integrin. Markers were set using unstained cells. Data are representative of three 
independent experiments.  
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Figure 4.8  SGVHD CD4+ T cell line proliferates against bacterial-Ag pulsed DC 
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Figure 4.8  SGVHD CD4+ T cell line proliferates against bacterial-Ag pulsed DC. SG6 
cells were harvested 8-10 days after initiation of culture and 1-2 x 105 cells were cultured 
in 96-well flat-bottomed microtiter plates with 1 x 104 antigen-pulsed DC. Proliferation 
was measured by the addition of [3H]-thymidine during the last 18 h of a 96 h culture. 
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Figure 4.9  Increased homing of CD4+ T cells into the gut of CsA-treated mice 
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Figure 4.9  Increased homing of CD4+ T cells into the colon of CsA-treated animals. 
SG6 cells were labeled with CFSE and injected (i.v.) into the tail of control or CsA-
treated animals at day 21 post-BMT. After 24 hr, their distribution into the colon was 
visualized under a fluorescent microscope (A). Labeled SG6 cells were counted, within a 
microscope field, over a 100x magnification (B). The mean values and their standard 
error were determined from two independent experiments containing a total of four 
animals per experimental group. 
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Figure 4.10  Elevated CD4+ T cell expression in liver tissue of SGVHD mice 
 
Figure 4.10 Elevated CD4+ T cell expression in liver tissue of SGVHD mice. 
Immunohistochemistry staining revealed increased CD4+ T cells in colonic tissue of 
SGVHD mice (day 37). Colon tissue from control BMT and CsA animals was collected 
at several time points (Days 14, 21 and 37) and frozen sections were stained for the 
presence of CD4+ T cells. Colons from CsA-treated animals (top panel) showed increased 
levels of CD4 staining at day 37 post-BMT compared to control BMT (lower panel). The 
data presented are representative of n=4 at days 14, 21 and n=6 at day 37 from two 
individual experiments. 
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Figure 4.11  MAdCAM-1 mRNA expression post-BMT in liver tissue 
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Figure 4.11  MAdCAM-1 mRNA expression post-BMT in liver tissue. BMT was 
performed as described.  At times after BMT, control and CsA-treated animals were 
killed, livers were removed and RNA prepared. Expression of MAdCAM-1 was 
determined at day 14 (A) and day 21 (B) post-BMT by real time RT-PCR and normalized 
to GAPDH. Data presented are the mean ± SEM from 1 experiment, with n=8. 
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CHAPTER FIVE: DISCUSSION 
 
5.1 Synopsis 
Syngeneic GVHD can be induced in mice by reconstituting lethally irradiated 
animals with syngeneic BM cells followed by a 21 day treatment with the 
immunosuppressive agent CsA [55]. Clinical symptoms of the disease, which include 
weight loss and diarrhea, appear 2 to 3 weeks after cessation of CsA therapy and 
SGVHD-associated inflammation occurs primarily in the colon and liver [55].  Both 
radiation and CsA are preconditioning requirements for the development of SGVHD [57, 
85] and participate in the induction of oxidative stress [65, 86-88]. SGVHD development 
is a multi step process resulting from the cooperative interaction of various effector cell 
populations including NK cells [80], T cells [78, 97] and macrophages [83], along with 
TH1 cytokines that result as a consequence of the preconditioning regimens of this disease 
[80, 83]. A proposed mechanism of action of these proinflammatory mediators in 
SGVHD is via their stimulation of oxidative stress. The role of oxidative stress, 
specifically NO during active disease has been previously studied. Inhibition of iNOS 
resulted in decreased development of SGVHD [100]. These findings, along with the 
implication of oxidative stress production by the conditioning regimens, led us to 
hypothesize that CsA-treated mice produce elevated levels of ROS/RNS compared to 
control BMT and to investigate the role of oxidative stress in the induction of SGVHD. 
Since previous studies have demonstrated a role for CD4+ T effector cells in the induction 
of murine SGVHD [58, 78], studies were undertaken to follow the migration of T cells at 
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the early stages after BMT and investigate the mechanism that could result in the 
increased migration of CD4 effector cells during the induction protocol of SGVHD. 
5.2 Role of oxidative stress in SGVHD 
In Chapter Three of this dissertation we examined the role of oxidative stress in 
SGVHD. This inducible disease was first described by Glazier et al. as a GVHD-like 
syndrome that developed in rats following syngeneic BMT and CsA treatment [16]. Both 
irradiation and CsA treatment are required for disease induction [57, 85] and participate 
in the production of oxidative stress [86-90]. We became interested in studying oxidative 
stress in the murine model of SGVHD since previous work had demonstrated a 
significant role for oxidative stress mediators during active disease [100]. Flanagan et al. 
determined the contribution of NO to the development of SGVHD by demonstrating that 
in vivo inhibition of iNOS with the inhibitor aminoguanidine (AG), starting on day 21 
post-BMT for up to 2 weeks (post-CsA therapy), significantly reduced the development 
of disease. In their studies, iNOS inhibition resulted in the abrogation of clinical 
symptoms, tissue pathology and cytokine (IL-12 and IFN-γ) production associated with 
the development of SGVHD [100]. In accordance, Garside et al. [105] showed that 
inhibition of iNOS with L-NG-monomethyl arginine (L-NMMA), in their experimental 
model of mice GVHD, resulted in decreased intestinal pathology. In addition to these 
studies looking at the effect of post-CsA iNOS inhibition, studies in allogeneic GVHD 
have shown that inhibition of NO production at early stages following BMT can lead to 
mortality [98, 106], suggesting that NO levels could affect alloengraftment [98] or have a 
protective effect during this period [106]. For this reason we decided to treat mice with 
the antioxidant MnTBAP, since it can scavenge a broad spectrum of reactive oxygen as 
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well as nitrogen species [126, 135, 136, 151]. Experiments were designed to investigate 
the role of oxidative stress during the induction of SGVHD by treating mice with 
MnTBAP during the CsA treatment period after BMT (days 0-21), as well as during the 
post-CsA period.  
In the immediate post-BMT period, conditioning and CsA treatment resulted in 
elevated production of inflammatory mediators. It was demonstrated that mice treated 
with CsA had increased levels of oxidative stress shown by increased levels of the ROS 
probe DCFH-DA. Staining of spleen lymphocytes taken from control BMT and CsA-
treated mice at day 21 post-CsA (Figure 3.1, A) and 2-3 weeks post-CsA therapy 
(Figure 3.1, B) revealed increased levels of this ROS marker in CsA-treated mice 
compared to transplant controls. Reactive nitrogen species were also elevated in the CsA-
treated animals compared to their control. Real time RT-PCR analysis revealed elevated 
mRNA levels of iNOS in colons of CsA-treated mice (Figure 3.2, A) and analysis of the 
serum showed elevated circulating nitrate in CsA animals (Figure 3.2, B) compared to 
control BMT. Along with increases in oxidative stress, our group has shown increased 
mRNA levels of TNF-α in the colons of CsA-treated mice compared to control BMT at 
several time points during and post-CsA therapy (Figure 4.3). It is known that irradiation 
can trigger TNF-α expression in many cell types and reports show that TNF-α signaling 
is associated with increased oxidative stress [94, 152]. Collectively, our results confirm 
that CsA-treated mice produce increased levels of oxidative stress compared to control 
transplanted mice.  
Simmonds et al. previously published a direct correlation between increased 
production of ROS and increased pathogenesis in colorectal biopsy specimens of patients 
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with inflammatory bowel disease [153]. Similarly, Rachmilewitz et al. also reported 
increased concentrations of RNS (i.e. NO) in ulcerative colitis and Crohn’s disease 
patients [154]. Thus, evidence exists of increased oxidative stress intermediates in IBD 
which could participate in the cellular damage and chronic inflammation observed in 
intestinal inflammation. Such findings point to the potential of antioxidant therapy as a 
possible curative option to ameliorate the deleterious effects caused by oxidative stress. 
Several studies have concentrated on the use of antioxidant therapy as an option to treat 
colitis and results reveal positive outcomes [155, 156]. The use of antioxidants to 
promote graft acceptance in animal models has also been successful, supporting the role 
of ROS/RNS in rejection [157]. In addition, antioxidant therapy in a murine model [158] 
as well as in a clinical trial [62] of GVHD has also been shown to improve disease 
outcome. These studies led us to the hypothesis that antioxidant therapy could ameliorate 
the inflammatory response observed in the colons of SGVHD animals. 
The potential and beneficial effect of SOD mimetics have been demonstrated in 
many studies, highlighting the importance of antioxidant compounds as potential 
therapeutic treatment for many pathologies (i.e. renal and myocardial ischemia and 
reperfusion (I/R) injury, inflammatory conditions, pulmonary diseases) [126, 133-135, 
151]. Therapy of CsA-treated mice with MnTBAP either during (Figure 3.4) or post-CsA 
(Figure 3.7) treatment resulted in the reduction of clinical symptoms and total disease 
induction. The use of antioxidant therapy in the murine model of SGVHD also reduced 
mRNA levels of iNOS (Figures 3.5, A and 3.8) and TNF-α (Figure 3.5, B) along with 
decreased nitrotyrosine staining (Figures 3.6, 3.9) in colonic tissue of CsA-treated mice 
compared to mice receiving CsA alone. These results demonstrated that MnTBAP 
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therapy of CsA-teated mice was capable of reducing RNS (i.e. iNOS and ONOO-), 
avoiding the possible damage caused by their elevated levels and/or their downstream 
products (i.e. radical-driven oxidative events). Peroxynitrite has been shown to change 
cell membrane rigidity and permeability as well as to induce cell death in renal epithelial 
cells [159]. A reduction in peroxynitrite could explain why MnTBAP treatment delayed 
the clinical symptoms of SGVHD by reducing ONOO⎯ induced damage to epithelial 
cells, resulting in reduction in diarrhea and weight loss. In addition to reducing 
proinflammatory mediators, MnTBAP therapy during CsA treatment also reduced the 
levels of CAM (data not shown) which contribute to the inflammatory response observed 
in this inducible disease (discussed in Chapter Four of this dissertation), The link that 
exists between CAM and lymphocyte homing to the site of inflammation has been 
documented in many pathologies [109, 113, 116, 160]. Thus MnTBAP-induced 
downregulation of CAM could affect lymphocyte homing to the inflamed gut observed in 
SGVHD.  
Since the role of CD4+ T cells has been well established in the pathogenesis 
observed in murine SGVHD [78, 161] and MnTBAP is capable of reducing CAM which 
contribute to T cell homing into the gut [109, 110, 116] (Chapter Four and discussed 
below), it could be hypothesized that antioxidant treatment could reduce the migration of 
CD4+ effector T cells into the colon of CsA-treated animals prior to development of 
disease. However, our results showed that the cellular inflammatory response observed in 
the colon of SGVHD was not reduced by MnTBAP treatment (Figure 3.10) and CD4+ T 
cells still migrated into the colons of CsA-treated mice after antioxidant therapy (Figure 
3.11). These interesting findings suggest that while MnTBAP decreased some 
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inflammatory mediators (i.e. iNOS, TNF-α and CAM), as well as reduced clinical 
symptoms and delayed disease induction, treatment of mice with this antioxidant was not 
enough to prevent the histological changes observed in the SGVHD colon. Since the 
effector cytokines and CAM were not significantly reduced by MnTBAP, these changes 
may not have been enough to alter the migration of effector cells into the gut, but may 
reduce the negative effects of oxidative stress on the development of clinical symptoms.  
The pathophysiology caused by ONOO⎯ on gut inflammation (i.e. IBD) has been difficult 
to predict since there are many oxidative mediators present during intestinal 
inflammation and neutralization of a specific mediator has been difficult. However, 
evidence does exist that both ROS and RNS are elevated in IBD, but their exact 
contribution remains unclear due to the lack of specificity of these scavengers [99]. 
 MnTBAP has been commercially sold as an SOD mimetic and there is some 
recent evidence that it may not be a specific scavenger of superoxide [133, 137]. 
Experiments using this compound suggested that commercial MnTBAP is unable to 
dismutate superoxide in vivo and has been reported to likely scavenge peroxynitrite and 
carbonate radicals [133]. In our attempt to discover the mechanism of action by which 
MnTBAP delayed the development of SGVHD, we analyzed mRNA levels of antioxidant 
enzymes including: SOD, catalase, glutathione reductase (GPx) and NADPH reductase. 
Real time RT-PCR results revealed that MnTBAP treatment had no effect on any of these 
antioxidant enzymes (data not shown) in the murine model of SGVHD. These results 
were surprising since other publications have shown that MnTBAP treatment induces 
upregulation of antioxidant enzymes [162, 163]. However, there is also evidence that the 
preconditioning requirements (irradiation and CsA) of SGVHD by themselves can 
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downregulate antioxidant enzyme activity [66, 164, 165], thus it is possible that the 
regimens induced oxidative stress via the downregulation of antioxidant defenses which 
could not be overcome by MnTBAP treatment. Analysis of nitrotyrosine deposition 
revealed decreased immunohistochemical staining of this marker, suggesting that 
MnTBAP antioxidant action may be through inhibiting tyrosine nitration rather than 
scavenging super oxide [133]. In addition, Cooke et al. showed that under oxidative 
stress, ONOO⎯ formation is enhanced, resulting in a positive loop that increases iNOS 
through the activation of NF-κB.  The possibility exists that MnTBAP treatment 
scavenged ONOO⎯ resulting in the reduction of NF-κB-induced expression of iNOS that 
we observed in the murine model of SGVHD [166]. This could explain why MnTBAP 
treatment both during and post-CsA period was able to reduce iNOS mRNA levels in 
colonic tissue of CsA-treated mice. Flanagan et al. demonstrated that SGVHD can be 
reduced following treatment with the iNOS inhibitor AG during the post-CsA period 
[100]. In their studies, AG therapy of CsA-treated mice resulted in decreased tissue 
pathology along with reduced mRNA levels of proinflammatory cytokines (i.e. IL-12 and 
IFN-γ). Surprisingly, in our studies, antioxidant therapy of CsA-treated mice with 
MnTBAP did not have the same effect.  
Differences between these therapies may rely in their mode of action. 
Aminoguanidine specifically inhibits iNOS [104] by causing covalent modifications of 
the iNOS protein and the heme residue at the active site resulting in inactivation of iNOS 
[167]. Meanwhile, MnTBAP has been reported to scavenge a broader spectrum of 
oxidative stress mediators. Thus, it is possible that while AG treatment was able to 
effectively shut down iNOS enzymatic activity and the generation of RNI, MnTBAP 
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therapy only decreased it partially through negative feedback loops [166] which resulted 
in a reduction in the production of NO and downstream generation of ONOO⎯.  Flanagan 
et al. demonstrated a role for NO in the pathogenesis observed in SGVHD but the 
mechanism of NO-induced inhibition remained unclear. It was unknown if AG action 
was via the reduction of cytotoxic processes or via the reduction of inflammatory 
cytokines. Tissues isolated from SGVHD animals treated with AG revealed decreased 
mRNA levels for IL-12 and IFN-γ, suggesting NO participated in the production of these 
cytokines [100]. This finding is consistent with the studies of Zhao et al. [168] showing 
that NO can upregulate the production of IL-12 by alveolar macrophages. Meanwhile in 
the current studies outlined in Chapter Three of this dissertation, MnTBAP therapy did 
not decrease mRNA levels of these proinflammatory cytokines (Figure 3.6), which are 
known to mediate disease induction [80]. It has been shown that NO enhances IL-12 
production which in turn stimulates NK cells to produce IFN-γ [169], suggesting that NO 
is a prerequisite for cytokine signaling and function. Our results support the idea that NO 
acts upstream of the induction of these proinflammatory cytokines since iNOS mRNA 
levels are significantly upregulated as early as day 14 post-BMT whereas significant 
increases of IL-12 or IFN-γ are not detected until day 21 post-BMT [100]. This could 
explain why AG treatment was able to decrease tissue pathology, while MnTBAP 
treatment did not, by reducing NO-induction of proinflammatory cytokines. Thus, while 
MnTBAP can alter NO production and other processes associated with RNS, it may not 
be as effective as AG in altering SGVHD pathology.   
The preconditioning regimen of SGVHD, which includes irradiation and CsA, are 
both known to participate in the generation of oxidative stress.  The data presented in 
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Chapter Three of this dissertation confirms the hypothesis that SGVHD induction results 
in increased oxidative stress in CsA-treated mice compared to BMT controls. Treatment 
with a commercially available SOD mimetic, MnTBAP, during the 21 days of CsA 
period as well as post-CsA treatment resulted in delayed disease induction and clinical 
symptoms of SGVHD. However, based on the findings outlined in this dissertation, we 
conclude that the reduction of proinflammatory mediators and oxidative stress was not 
sufficient to completely ameliorate disease induction.  
5.3 Role of T cell homing in SGVHD 
 Leukocyte homing from the blood to different compartments of the body 
is governed by complex signal cascades and interactions involving selectins and 
integrins, found on the inflamed tissue, and their respective ligands on the surface of 
lymphocytes [2]. A role for CD4+ T cells in the development of SGVHD has clearly been 
established [58, 78]. First, tissue analysis revealed an increased percentage of CD4+ T 
cells in the SGVHD colons and further characterization confirmed these findings [78]. In 
vivo depletion studies using a mAb containing a cocktail against T cells during the post-
CsA period failed to inhibit disease [80] and subsequent analysis revealed that antibody 
treatment was able to remove peripheral CD4+ T cells but not colonic T cells [78] thus 
not altering SGVHD induction. Expanding on these studies, the use of specific mAb 
against CD4+ T cells, following myeloablative conditioning and during the 21 days of 
CsA therapy period, significantly reduced the induction of clinical symptoms as well as 
pathology associated with murine SGVHD [78]. Along these findings, there is also 
evidence that CD4+ T cells isolated from SGVHD mice are capable of inducing disease 
when adoptively transferred into secondary recipients [58]. Taken together, these findings 
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demonstrate that the presence of CD4+ T cells in the colons of CsA-treated mice during 
the induction period is critical for disease development. In Chapter Four of this 
dissertation, experiments were performed to follow up on the observation that CD4+ T 
cells accumulate in the colon during CsA therapy [80] and to study potential mechanisms 
involved in trafficking of these cells into the colon of CsA-treated mice. Real time RT-
PCR mRNA analysis revealed increased levels of the proinflammatory cytokine TNF-α 
(Figure 4.3), as well as CAM (Figures 4.4 and 4.6) in colonic tissue of CsA-treated 
mice compared to control BMT as early as day 14 post-BMT. In addition, chemokines 
associated with the migration of T cells into mucosal tissues were also significantly 
elevated in the CsA-treated mice by day 21 post-BMT (Figure 4.6). Concurrent with 
these results, lymphocytes isolated from the colons of CsA-treated mice showed a 
significant increase in the percentage of CD4+ T cells compared to control animals 
(Figures 4.1 and 4.2).  
 The conditioning agents of SGVHD (CsA and irradiation) have been shown to 
damage the vascular endothelium [92, 170] resulting in the upregulation of 
proinflammatory cytokines such as TNF-α. It was proposed that this inflammatory 
cascade resulted in the upregulation of CAM, which in turn enhanced the recruitment of 
leukocytes to the site of inflammation. Numerous studies have shown the important 
function that CAM have in different pathologies, as well as their role in lymphocyte 
homing to the inflamed organ [108-110, 116, 117, 142, 160]. Since our studies 
concentrated on the colon, we focused on the expression of MAdCAM-1 because it has 
been previously demonstrated to be essential in the induction of intestinal GVHD [117]. 
The α4β7 integrin serves as the ligand for MAdCAM-1 and their interaction has been 
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strongly implicated in directing the recruitment of lymphocytes to the inflamed intestine 
[117, 171]. Eyrich et al. have shown that irradiation enhances the expression of VCAM 
and ICAM, but not MAdCAM by three days after radiation conditioning and syngeneic 
BMT [117].  The expression of these molecules subsided by nine days after BMT.  
Additional signals involved in the induction of allogeneic GVHD were required for the 
upregulation of MAdCAM in these studies. These additional signals were likely 
generated as a result of the allogeneic T cell response associated with the development of 
allogeneic GVHD.  Based on the sequential expression of CAM following allogeneic 
BMT and GVHD induction [117], and the enhanced migration of CD4+ T cells into the 
colon during CsA treatment in the SGVHD model, studies were initiated to examine the 
expression of CAM after BMT, during the CsA treatment period (d0-d21).  Analysis of 
colonic tissue revealed significantly increased mRNA levels of CAM as early as day 14 
post-BMT in CsA-treated mice compared to control BMT (Figures 4.4 and 4.5). 
Concurrent with these findings, significantly elevated levels of CD4+ T cells were also 
observed in the colon of CsA-treated mice at this early time point (Figures 4.1 and 4.2). 
It should be noted that in contrast to the CsA therapy of BMT mice, preliminary studies 
have shown that treatment of normal, non-irradiated animals with CsA did not induce the 
influx of CD4+ cells into the colon (data not shown), further demonstrating the dual 
requirement for pretransplant conditioning and CsA treatment in the development of 
SGVHD [57, 85, 97]. In addition, TNF-α mRNA levels were also significantly elevated 
by day 14 post-BMT in the colon mice treated with CsA compared to transplant control 
(Figure 4.3). Since the level of this proinflammatory molecule was significantly elevated 
during the CsA period, preliminary experiments were performed to analyze the role that 
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TNF-α may have in the induction phase of SGVHD.  However, attempts to decrease 
TNF-α, by in vivo neutralization, was associated with a high mortality rate in the treated 
animals. Similar results have been previously reported in which TNF-α neutralization in 
the early post-BMT period resulted in increased mortality in an allogeneic BMT model 
system [172]. These results suggest that TNF-α has a protective effect during the early 
stages after BMT and is essential for recipient survival.   
 Histological evaluation of colonic tissue during active disease, as well as analysis 
of isolated cells, has led to the recognition that the severe colonic tissue damage observed 
in SGVHD mice is caused by an infiltration of inflammatory CD4+ T cells into the colon 
of CsA-treated mice [55, 78, 80, 83, 100, 139]. The mechanism by which effector T cells 
are recruited into the gut during the inflammatory response of SGVHD remains unclear 
but a potential contributor likely involves chemokine gradients. Chemokine interactions 
with their corresponding receptors have been implicated in many inflammatory processes 
via their ability to attract effector cells to the sites of inflammation [112, 113, 160]. 
Several studies have been able to characterize chemokines highly expressed during gut 
inflammation which include CCR5, CCL3, CCL5 and CCL20 [112, 113]. We therefore 
analyzed the mRNA expression of these chemokines in colonic tissue and similar to the 
elevated levels of CD4+ T cells and CAM, these chemokines associated with gut 
inflammation were also significantly increased in the colon of CsA-treated mice by day 
21 post-BMT compared to control (Figure 4.6). The mRNA levels of these chemokines 
were also evaluated at day 14 post-BMT but at this time point only CCR5, which is 
expressed on the surface of activated lymphocytes, was significantly elevated (data not 
shown). However, its ligands (CCL3 and CCL5) were only slightly, but consistently 
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elevated, when compared to control BMT. No difference was observed in mRNA levels 
of CCL20 by day 14 post-BMT. While activated lymphocytes expressing CCR5 were 
present by day 14 post BMT, its counterligands, released by the tissue, were not yet up-
regulated at this early time point, suggesting that other ligand-receptor pairs may be 
involved in the early homing of these T cells into the intestines of CsA mice. Changes in 
the expression levels of homeostatic chemokines, including CCL19, CCL21, CCL25, 
CCL28, as well as CXCL13 have been shown to be increased in IBD [113]. Thus, we 
cannot discard the possibility that other mediators are involved in the recruitment of these 
CD4+ T cells to the inflamed tissue since high levels of redundancy are involved in 
chemokine receptor function and inflammatory responses. 
To determine if the increases in CAM and chemokines were functional during the 
SGVHD induction period, a long-term CD4+ T cell line, originally isolated from diseased 
animals, was used for lymphocyte trafficking studies. Previous results [58] and 
unpublished data, have demonstrated that an increased frequency of CD4+ T cells in 
lymphoid cells isolated from SGVHD animals are reactive against microbial antigens 
present in the cecum of normal mice. Phenotypic analysis of these cells showed that they 
express β7 integrin, which is a type of integrin expressed on the cell surface of activated 
lymphocytes and allows for their interaction with cell adhesion molecules (MAdCAM-1, 
VCAM-1) present in the inflamed gut. Our results showed increased mRNA levels of 
these CAM in colonic tissue of CsA-treated mice compared to control BMT as early as 
day 14 post-BMT (Figures 4.4 and 4.5). Concurrent with these findings, preliminary 
studies on IEL, isolated from the colon of control and CsA-treated mice at several time 
points during the induction protocol, revealed a 2-fold increased in CD4+β7+ lymphocytes 
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in the colons of CsA animals by day 14 pos-BMT (data not shown). These results 
allowed us to hypothesize that CD4+ T cells, isolated from diseased animals and bearing 
the β7 integrin, would preferentially migrate into the colon of CsA-treated mice which 
express elevated levels of CAM. Homing studies performed by i.v. inoculation of the 
labeled CD4+ SGVHD T cell line at day 21 post-BMT, revealed their increased migration 
into the colon of CsA-treated mice compared to control BMT, suggesting a functional 
role for the increased CAM and inflammatory mediators present in the intestines of CsA-
treated mice. In this study, the migration and distribution of these CD4+ T cells was also 
analyzed in other tissues including the liver, spleen and lung. In addition to the intestine, 
increased numbers of these labeled CD4+ T cells were also observed in liver tissue of 
CsA-treated mice compared to control BMT animals, although not to the extent observed 
in the colon (data not shown).  
The results presented in the Chapter Four of this dissertation demonstrates that 
during the 21 days of immunosuppressive therapy there is an ordered increase in the 
expression of inflammatory mediators and CAM that is associated with the increased 
migration of CD4+ T effector cells into the colon, leading to the development of the 
colonic inflammation associated with murine SGVHD. 
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5.4 Proposed mechanism underlying oxidative stress and T cell role in 
the pathogenesis observed in murine SGVHD 
 To summarize our findings, we propose the following mechanism for the 
involvement of oxidative stress and T cell homing in murine SGVHD. Total body 
irradiation is a preconditioning regimen required for the induction of SGVHD. It is 
known that it upregulates production of oxidative stress as well as proinflammatory 
cytokines. As a consequence, immune cells along with ROS/RNS mediate tissue damage 
and initiate a cascade of inflammatory responses. Damage to the gastrointestinal tract 
allows for increased translocation of LPS and other microbial molecules into the systemic 
circulation. These bacterial products can lead to the stimulation of macrophages to 
produce proinflammatory mediators like TNF-α, IL-12 and NO. Tumor necrosis factor-α 
can in turn activate NF-κB induction of gene transcription of proinflammatory molecules 
resulting in increased cytokines, adhesion molecules and oxidative stress mediators 
involved in immune and inflammatory responses. In turn, IL-12, also known as a T cell 
stimulating factor, can stimulate the growth/function of the CD4+ T cells known to 
mediate SGVHD, resulting in the production of IFN-γ which can feed back and further 
enhance macrophage activation. Macrophages can produce NO via iNOS leading to 
inflammation by upregulation of oxidative stress mediators. Nitric oxide by itself is a 
weak free radical but its combination with other ROS, like superoxide (O2-), can result in 
the formation of peroxynitrite (·O2− + ·NO → ONOO−), a very toxic and reactive product 
capable of mediating several cytotoxic processes. CsA, another preconditioning agent of 
SGVHD, is also involved in upregulation of oxidative stress and its proposed mechanism 
is via the down regulation of antioxidant enzymes leading to the accumulation of 
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ROS/RNS. All these proinflammatory mediators can then act in concert to induce the 
lesions and pathology observed in the colon of SGVHD mice.   
 In addition, the elevated inflammatory signals (TNF-α, oxidative stress 
mediators/products) can also upregulate CAM on the surface of HEV present in the 
epithelium, allowing for the homing and extravasation of lymphocytes into the gut. APC 
present at the site of inflammation migrate into the MLN were they present microbial 
antigens and activate CD4+ T cells. Once activated, these CD4+ T cells express in their 
surface β7 integrin which allows for their interaction with CAM present in the inflamed 
colonic tissue. Chemokines released by the tissue serve to attract these CD4+ T cells to 
the site of inflammation. The colonic CD4+ T cells can further enhance other effector 
cells, expanding the inflammatory response leading to tissue damage. Activation of CD4+ 
T cells in the MLN/colon leads to an IBD-like disease that moves from the colon to the 
liver by aberrant expression of CAM (MAdCAM-1) and chemokines (CCL25) that are 
typically restricted to the epithelium of the gut mucosa. These CD4+ T cells, as well as 
other inflammatory cells (macrophages, Kuppfer cells, dendritic cells (DC)), work 
together to mediate intra- and extra-hepatic liver inflammation that develops subsequent 
to the colonic inflammation (see Figure 5.1).  
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5.5 Future directions 
The studies performed in this dissertation offer new findings that contribute to the 
understanding of the IBD-like colitis observed in murine SGVHD. Besides the 
contributing knowledge that these results provide they also give rise to further questions 
which require additional studies for their analysis.  
In Chapter Three of this dissertation the role of oxidative stress in the 
development of SGVHD is discussed. Even though treatment with the antioxidant 
MnTBAP delayed disease induction it was not sufficient to inhibit disease or the 
contributing effector cells and cytokines associated with the pathology observed in 
SGVHD animals. The usage of this antioxidant at a higher dose (20 mg/kg, twice a day) 
but still under the safe concentration to be used following a toxicological report, resulted 
in increased mortality of mice (data not shown). Suggesting that combined treatment of 
CsA along MnTBAP had a toxic effect on mice, which was confirmed by increased 
pathology in colon and liver samples. In addition, MnTBAP action on scavenging 
ROS/RNS mediators has been somehow controversial and could result in misleading 
conclusions. It is evident that oxidative stress is increased in CsA-treated mice compared 
to control BMT but its exact contribution to the development of murine SGVHD during 
the 21 days of immunosuppression therapy remains unclear, thus requiring further studies 
to better analyze this matter. This approach can be studied by the use of a more specific 
antioxidant, like M40403, which is an SOD mimetic that specifically scavenges super 
oxide anions at a high rate, inhibiting its interaction with other biological oxidizing 
agents. This could provide a better understanding and specificity of the role of super 
oxide in SGVHD.  
111 
 
The role of T cell homing in SGVHD was discussed in the fourth chapter of this 
dissertation leading to the findings that there are mechanisms occurring during the period 
of CsA treatment that allow for increased migration of CD4+ T cells into the colon of 
CsA-treated mice compared to control BMT. Cell adhesion molecules seem to be 
implicated in the homing of these T cells into the gut, specifically MAdCAM-1 via its 
interaction with α4β7+ present in the surface of activated T cells. Although significant 
increases in both CAMs and β7+ were present in colonic tissue of CsA-treated mice 
immunoblockade studies were not undertaken to confirm the role of these mediators in 
murine SGVHD. Further in vivo studies either blocking MAdCAM-1 or α4β7+ are 
required to study their effect on T cell migration and SGVHD outcome.  
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Figure 5.1  Role of oxidative stress and T cell homing in murine SGVHD 
 
Figure 5.1  Role of oxidative stress and T cell homing in murine SGVHD. Irradiation 
and CsA treatment upregulate the production of oxidative stress as well as 
proinflammatory cytokines. Damage to the GI tract allows for increased translocation of 
bacteria products which stimulate MΦ to produce proinflammatory mediators. 
Chemokines released by the tissue serve to attract bacterial-specific CD4+ T cells to the 
site of inflammation, expanding the inflammatory response and leading to further tissue 
damage. Activated CD4+ T cells move from the colon into the liver by aberrant 
expression of MAdCAM-1 and CCL25 that act in concert with other inflammatory cells 
to mediate the liver inflammation that develops subsequent to the colonic inflammation. 
113 
 
Appendix. Reagent Preparation 
 
Phosphate Buffer Saline (PBS) Solution: 
For a 10X solution: 
1. Add 92 g of NaH2PO4 (dibasic) to 4 liters of distilled water 
2. Heat solution to 60⁰C in a water bath, stirring periodically to dissolve 
3. While solution is still stirring, add 16 g of KH2PO4 
4. Adjust pH to 7.2 
5. Add 654.4 g NaCl to the stirring solution 
6. Bring total volume to 8 liters with distilled water 
7. Store at room temperature 
For a 1X solution: 
1. Combine 100 ml of 10X PBS with 900 ml distilled water 
 
Paraformaldehyde solution: 
For a 1% paraforlmaldehyde solution: 
1. Combine 1 g paraformaldehyde with 25 ml of distilled water and incubate in a 
56⁰C water bath, stirring occasionally until dissolved 
2. Add 5 ml of 10X PBS and 20 ml distilled water to the solution and mix 
3. Add 5 ml of 10X PBS and 45 ml distilled water to the solution and mix 
4. Adjust  pH to 7.4 
5. Filter solution and place in a 100 ml bottle 
6. Store at 4⁰C refrigerator 
For a 3% paraforlmaldehyde solution: 
1. Prepare 1 liter of 0.1M PBS by mixing 3.58 g NaH2PO4●2H2O (monobasic) + 
10.94 g NaH2PO4 (dibasic) and complete to 1 liter with distilled water 
2. Add 30 g of paraformaldehyde to 900 ml of PBS 
3. Heat solution to 60⁰C in a water bath, stirring periodically, until solution is clear 
4. Allow solution to cool to room temperature 
5. Adjust pH to 7.2-7.4 
6. Bring total volume to 1 liter with PBS 
7. Store at 4⁰C 
 
Tris-buffer stock: 
1. Dissolve 20.59 g of Triza Base into 800 ml distilled water 
2. Adjust pH to 7.2 
1. Bring total volume to 1 liter with distilled water 
3. Autoclave 20 min, slow exhaust to sterilize 
4. Store at room temperature 
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Tris-buffered ammonium chloride: 
2. Dissolve 8.3 g of NH4Cl in 800 ml of distilled water by stirring 
3. Add 100 ml of Tris-buffer stock, pH 7.2  
4. Adjust pH to 7.2 
5. Bring total volume to 1 liter with distilled water 
6. Dispense into 100 ml bottles and autoclave 20 min, slow exhaust to sterilize 
7. Store at room temperature 
 
Heat Activate Fetal Bovine Serum (FBS):  
1. Take out FBS from -20⁰C and allow flask to thaw in a 37⁰C water bath, stirring 
occasionally 
2. Once thawed, transfer FBS to 60⁰C water bath for 45 minutes 
3. Allow to cool down at room temperature 
4. Store at 4⁰C  
 
Complete Media (RPMI 1640): 
1. Add Fetal Bovine Serum (FBS): 
• For 10% media: 50 ml of FBS for each 500 ml bottle of RPMI  
• For 5% media: 25 ml of FBS for each 500 ml bottle of RPMI  
2. Add 5 ml of penicillin/streptomycin/glutamine (100X) 
3. Add 5 mM 2-mercaptoethanol (2-ME) 
4. Store at 37⁰C 
  
Cytotoxic Media (RPMI 1640): 
1. Add 5 ml of penicillin/streptomycin/glutamine (100X) and 20 ml of bovine serum 
albumin (BSA) to one bottle of 500 ml RMPI 
2. Store at 37⁰C 
 
Hepes Bicarbonate Buffer: 
1. Combine 23.8 g of Hepes with 21 g of NaCl 
2. Bring total volume to 1 liter with distilled water 
3. Adjust pH to 7.2  
4. Transfer into a sterile flask and store at room temperature 
 
0.5 M  EDTA Solution: 
1. Dissolve 16.81 g of EDTA in 90 ml of distilled water 
2. Adjust pH to 7.2  
3. Bring total volume to 100 ml with distilled water 
4. Autoclave 20 min, slow exhaust to sterilize 
5. Store at room temperature 
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CMF Solution:  
 
1. Combine 100 ml 10X Hanks (Ca2+, Mg 2+free), 100 ml 10x Hepes bicarbonate 
buffer and 20 ml FBS 
2. Bring total volume to 1000 ml with distilled water 
3. Filter sterilize and store at 4⁰C 
 
CMF/FBS/DTE/EDTA Solution; 
 
1. Combine 184 ml CMF, 16 ml FBS, 0.2 ml DTT (1M) and 0.4 ml EDTA (0.5M) 
2. Prepare fresh and place in 37⁰C water bath until use 
 
10% Complete /Collagenase Type VIII/DNaseI Solution: 
1. Combine 80 ml 10% complete RMPI, 69.3 mg Collagenase (277U/mg) and  
0.080 mg DNaseI (2000U/mg) 
2. Prepare fresh and place in 37⁰C water bath until use 
 
Percoll Soutions: 
 
1. Prepare a 1X stock solution by diluting 90 ml Percoll with 10 ml of 10X PBS 
2. For a 44% Percoll solution: Mix 44 ml of 1X stock and 56 ml 5% complete 
medium 
3. For a 67% Percoll solution: Mix 67 ml of 1X stock and 33 ml 5% complete 
medium 
4. Adjust pH to 7.2 
5. Prepare fresh and place on ice until use 
 
FACS Staining Buffer: 
 
1. Combine 5 ml FBS, 50 mg NaN3 into a flask containing 500 ml 1X PBS and mix 
to dissolve 
2. Store in 4⁰C 
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